```
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
FILE 'HOME' ENTERED AT 13:39:25 ON 27 APR 2005
=> file biosis caba caplus embase japio lifesci medline scisearch uspatfull
=> e hochstrasser denis/au
E1          467     HOCHSTRASSER D F/AU
E2           22     HOCHSTRASSER D L/AU
E3           49 --> HOCHSTRASSER DENIS/AU
E4            1     HOCHSTRASSER DENIS E/AU
E5          320     HOCHSTRASSER DENIS F/AU
E6            1     HOCHSTRASSER DENIS FRAN CEDILLA OIS/AU
E7            1     HOCHSTRASSER DENIS FRANCEDILLAOIS/AU
E8           28     HOCHSTRASSER DENIS FRANCOIS/AU
E9            1     HOCHSTRASSER DF/AU
E10           1     HOCHSTRASSER DIETER/AU
E11           1     HOCHSTRASSER DONALD L/AU
E12           1     HOCHSTRASSER E/AU

=> s e1-e8 and spongiform
L1           19 ("HOCHSTRASSER D F"/AU OR "HOCHSTRASSER D L"/AU OR "HOCHSTRASSER
                DENIS"/AU OR "HOCHSTRASSER DENIS E"/AU OR "HOCHSTRASSER DENIS
               F"/AU OR "HOCHSTRASSER DENIS FRAN CEDILLA OIS"/AU OR "HOCHSTRASS
               ER DENIS FRANCEDILLAOIS"/AU OR "HOCHSTRASSER DENIS FRANCOIS"/AU)
                AND SPONGIFORM

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2            8 DUP REM L1 (11 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L2   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2005 ACS on STN  DUPLICATE 1
AN   2004:722816  CAPLUS
DN   141:239284
TI   Diagnostic method for transmissible  ***spongiform***  encephalopathies
IN     ***Hochstrasser, Denis Francois***  ; Sanchez, Jean-Charles; Guillaume,
     Elisabeth
PA   Switz.
SO   U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   US 2004171026        A1    20040902    US 2003-695194          20031028
     GB 2379737           A1    20030319    GB 2001-21459           20010905
     WO 2003023406        A2    20030320    WO 2002-EP10063         20020903
     WO 2003023406        A3    20031127
     WO 2003023406        C2    20040226
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
```

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-21459 A 20010905
WO 2002-EP10063 A2 20020903
GB 2002-25245 A 20021030
GB 2003-6290 A 20030319

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000.

L2 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:392701 CAPLUS
DN 140:371477
TI Diagnostic method for transmissible ***spongiform*** encephalopathies
IN Sanchez, Jean-Charles; ***Hochstrasser, Denis Francois*** ; Guillaume, Elisabeth
PA Proteome Sciences Plc., UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004040316	A2	20040513	WO 2003-GB4574	20031023
WO 2004040316	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-25245 A 20021030
GB 2003-6290 A 20030319

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000, but excluding the range of from 3500 to 30000. TSE can be diagnosed in a subject by detg. a test amt. of a polypeptide in a sample of body fluid, wherein the polypeptide is Cystatin C or a Hb, a Hb chain or a truncated chain or a fragment thereof which exhibits an immunol. reaction to an antibody to bovine Hb.

L2 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:222395 CAPLUS
DN 138:262426
TI Diagnostic method for ***spongiform*** encephalopathy disease
IN Guillaume, Elisabeth; ***Hochstrasser, Denis Francois*** ; Sanchez,

Jean-charles
PA Universite de Geneve, Switz.
SO Brit. UK Pat. Appl., 24 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2379737	A1	20030319	GB 2001-21459	20010905
	WO 2003023406	A2	20030320	WO 2002-EP10063	20020903
	WO 2003023406	A3	20031127		
	WO 2003023406	C2	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1423703	A2	20040602	EP 2002-767478	20020903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005502882	T2	20050127	JP 2003-527426	20020903
	US 2004171026	A1	20040902	US 2003-695194	20031028
PRAI	GB 2001-21459	A	20010905		
	WO 2002-EP10063	W	20020903		
	GB 2002-25245	A	20021030		
	GB 2003-6290	A	20030319		

AB Diseases such as BSE, CJD or scrapie are diagnosed in a subject by analyzing a sample of body fluid by mass spectrometry to det. the presence of a polypeptide marker of mol. wt. 3500 to 30000 where the polypeptide is present in different amts. in the body fluid of infected and non-infected subjects. The test sample may be adsorbed on a probe carrying an adsorbent material capable of binding the polypeptide. The material is e.g. a metal chelating group complexed with a metal ion. Kits for carrying out the diagnosis are also disclosed. The body fluid sample may be from humans or cattle.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 8 USPATFULL on STN
AN 2003:225768 USPATFULL
TI Diagnostic assay for transmissible ***spongiform*** encephalopathies
IN ***Hochstrasser, Denis Francois*** , Geneva, SWITZERLAND
Sanchez, Jean-Charles, Geneva, SWITZERLAND
Zimmermann, Catherine Gabrielle, Geneva, SWITZERLAND
Guillaume, Elisabeth, Annemasse, FRANCE
PI US 2003157580 A1 20030821
AI US 2002-238557 A1 20020910 (10)
RLI Continuation of Ser. No. WO 2001-EP2894, filed on 12 Mar 2001, UNKNOWN
PRAI GB 2000-5683 20000310
GB 2000-6064 20000314
DT Utility

FS APPLICATION
LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

L2 ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 2
AN 2004:60806 BIOSIS
DN PREV200400061254
TI A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease.
AU Guillaume, Elisabeth [Reprint Author]; Zimmermann, Catherine; Burkhard, Pierre R.; ***Hochstrasser, Denis F.*** ; Sanchez, Jean-Charles
CS Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, 24, Rue Micheli-du-Crest, 1211, Geneva 14, Switzerland
guillaum@dim.hcuge.ch
SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1495-1499. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004
AB The recent occurrence of the new variant of Creutzfeldt-Jakob disease (CJD), probably transmitted to humans by cattle affected by the bovine form of ***spongiform*** encephalopathy, has generated renewed interest in the clinical issues related to human ***spongiform*** encephalopathies. Using the current set of diagnostic tools, these rare but devastating conditions may be difficult to diagnose with accuracy before death. The objective of the present communication is to describe the discovery of a potential cerebrospinal fluid (CSF) and plasmatic marker of human transmissible ***spongiform*** encephalopathies. A preliminary two-dimensional electrophoresis approach highlighted a potential neurodegenerative disorder marker called the fatty acid binding protein, FABP. Its heart form, H-FABP, was investigated in a small group of CJD affected patients (n=8) by an immunoassay approach. The amount of FABP appeared to be significantly (pltoreq0.05) increased in all tested samples. H-FABP detection could therefore be helpful as a blood screening test for a pre-mortem diagnosis of the disease and also to prevent the risk of iatrogenic transmission of CJD through blood transfusion.

L2 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:677072 CAPLUS
DN 135:207875
TI Diagnostic assay for transmissible ***spongiform*** encephalopathies
IN ***Hochstrasser, Denis Francois*** ; Sanchez, Jean-Charles; Zimmermann, Catherine Gabrielle; Guillaume, Elisabeth

PA Universite de Geneve, Switz.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001067108	A2	20010913	WO 2001-EP2894	20010312
	WO 2001067108	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	GB 2360089	A1	20010912	GB 2000-5683	20000310
	CA 2402314	AA	20010913	CA 2001-2402314	20010312
	EP 1261875	A2	20021204	EP 2001-931527	20010312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003526788	T2	20030909	JP 2001-566030	20010312
	US 2003157580	A1	20030821	US 2002-238557	20020910
PRAI	GB 2000-5683	A	20000310		
	GB 2000-6064	A	20000314		
	WO 2001-EP2894	W	20010312		

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, esp. CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

L2 ANSWER 7 OF 8 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:488816 SCISEARCH
GA The Genuine Article (R) Number: 440RB
TI CSF detection of the 14-3-3 protein in unselected patients with dementia
AU Burkhard P R (Reprint); Sanchez J C; Landis T; ***Hochstrasser D F***
CS Univ Hosp Geneva, Dept Neurol, CH-1211 Geneva 14, Switzerland (Reprint); Univ Hosp Geneva, Cent Lab Clin Chem, CH-1211 Geneva, Switzerland
CYA Switzerland
SO NEUROLOGY, (12 JUN 2001) Vol. 56, No. 11, pp. 1528-1533.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 0028-3878.
DT Article; Journal
LA English
REC Reference Count: 26
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Objective: To determine the usefulness of the 14-3-3 test in patients with dementia of various causes. Background: Recent reports have suggested that the detection of the 14-3-3 protein in the CSF of patients with

Creutzfeldt-Jakob disease is a highly sensitive and specific marker of the disease that might be used as a diagnostic criterion. We examined the validity of this test when applied to a cohort of unselected patients prospectively examined for an ongoing dementing process. Methods: One hundred patients underwent an extensive neurologic examination for dementia, including a CSF 14-3-3 protein immunoblotting assay. Final clinical diagnoses were compared with the qualitative results of the test, and statistical measures of test validity were carried out. Results: We found a positive test in 14 of 100 patients, only two of whom had definite Creutzfeldt-Jakob disease. Positive results were found in patients with various degenerative dementias, including AD (4), frontotemporal dementia (2), and dementia with Lewy body (1), and in patients with vascular dementia (1), carcinomatous meningitis (1), and anoxic encephalopathy (1). in two other positive patients, the dementia could not be confidently classified. Sensitivity, specificity, and negative predictive value were fairly good, but positive predictive value was poor. Similar results were found independently of the disease duration. There was no correlation between intensity nor pattern of the 14-3-3 protein expression and diagnosis. Conclusions: The 14-3-3 test is not valid for discriminating between Creutzfeldt-Jakob disease and non-Creutzfeldt-Jakob disease in unselected patients with dementia. Positive results are found in various degenerative and secondary, prion-unrelated dementias.

L2 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 3
AN 1997:509954 BIOSIS
DN PREV199799809157
TI Elevation of apolipoprotein E in the CSF of cattle affected by BSE.
AU ***Hochstrasser, Denis F.*** ; Frutiger, Severine; Wilkins, Marc R.; Hughes, Graham; Sanchez, Jean-Charles [Reprint author]
CS Clinical Chem. Lab., Geneva Univ. Hosp., 24 Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
SO FEBS Letters, (1997) Vol. 416, No. 2, pp. 161-163.
CODEN: FEBLAL. ISSN: 0014-5793.
DT Article
LA English
ED Entered STN: 10 Dec 1997
Last Updated on STN: 10 Dec 1997
AB The cerebrospinal fluid (CSF) of patients suffering from Creutzfeldt-Jakob disease (CJD) display two unique polypeptide chains by two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). In the absence of a well-defined ante-mortem diagnostic test for bovine ***spongiform*** encephalopathy (BSE), spinal fluid samples of eight normal cows and eight cows known to carry BSE by postmortem histological analysis were investigated to verify if equivalent polypeptides were present. Proteins with similar migration to human CJD polypeptides were not detected. But surprisingly, a cluster of polypeptide spots that was faint or not detected in normal bovine CSF samples was found to be elevated or massively increased in BSE CSF samples (more than 10-fold increase). These elevated polypeptide chains were identified as apolipoprotein E.

```
=> e sanchez jean/au
E1          4     SANCHEZ JAVIER R/AU
E2          2     SANCHEZ JAVIER R M/AU
E3          2 --> SANCHEZ JEAN/AU
E4          1     SANCHEZ JEAN A/AU
```

```
E5          304      SANCHEZ JEAN CHARLES/AU
E6           23      SANCHEZ JEAN FREDERIC/AU
E7           16      SANCHEZ JEAN LOUIS/AU
E8            4      SANCHEZ JEAN PIERRE/AU
E9           64      SANCHEZ JEAN YVES/AU
E10           2      SANCHEZ JENNIFER/AU
E11           6      SANCHEZ JENNIFER F/AU
E12           1      SANCHEZ JENNIFER FREDERICK/AU

=> s e5 and spongiform
L3           11 "SANCHEZ JEAN CHARLES"/AU AND SPONGIFORM

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4            7 DUP REM L3 (4 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L4  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2005 ACS on STN  DUPLICATE 1
AN  2004:722816  CAPLUS
DN  141:239284
TI  Diagnostic method for transmissible  ***spongiform***  encephalopathies
IN  Hochstrasser, Denis Francois;  ***Sanchez, Jean-Charles***  ; Guillaume,
    Elisabeth
PA  Switz.
SO  U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
    CODEN: USXXCO
DT  Patent
LA  English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 2004171026        A1    20040902    US 2003-695194         20031028
     GB 2379737           A1    20030319    GB 2001-21459          20010905
     WO 2003023406        A2    20030320    WO 2002-EP10063        20020903
     WO 2003023406        A3    20031127
     WO 2003023406        C2    20040226
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2001-21459        A     20010905
     WO 2002-EP10063      A2    20020903
     GB 2002-25245        A     20021030
     GB 2003-6290         A     20030319
AB  Transmissible  ***spongiform***  encephalopathy (TSE) is diagnosed in a
    subject by using mass spectrometry to observe a polypeptide in a sample of
    body fluid taken from the subject.  The polypeptide is differentially
    contained in the body fluid of TSE-infected subjects and non-infected
    subjects, and has a mol. wt. in the range of from 1000 to 100000.
```

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:392701 CAPLUS
DN 140:371477
TI Diagnostic method for transmissible ***spongiform*** encephalopathies
IN ***Sanchez, Jean-Charles*** ; Hochstrasser, Denis Francois; Guillaume, Elisabeth
PA Proteome Sciences Plc., UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004040316	A2	20040513	WO 2003-GB4574	20031023
	WO 2004040316	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	GB 2002-25245	A	20021030
	GB 2003-6290	A	20030319

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000, but excluding the range of from 3500 to 30000. TSE can be diagnosed in a subject by detg. a test amt. of a polypeptide in a sample of body fluid, wherein the polypeptide is Cystatin C or a Hb, a Hb chain or a truncated chain or a fragment thereof which exhibits an immunol. reaction to an antibody to bovine Hb.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:222395 CAPLUS
DN 138:262426
TI Diagnostic method for ***spongiform*** encephalopathy disease
IN Guillaume, Elisabeth; Hochstrasser, Denis Francois; ***Sanchez,*** *** Jean-charles***
PA Universite de Geneve, Switz.
SO Brit. UK Pat. Appl., 24 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2379737	A1	20030319	GB 2001-21459	20010905
	WO 2003023406	A2	20030320	WO 2002-EP10063	20020903
	WO 2003023406	A3	20031127		

WO 2003023406 C2 20040226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1423703 A2 20040602 EP 2002-767478 20020903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005502882 T2 20050127 JP 2003-527426 20020903
US 2004171026 A1 20040902 US 2003-695194 20031028
PRAI GB 2001-21459 A 20010905
WO 2002-EP10063 W 20020903
GB 2002-25245 A 20021030
GB 2003-6290 A 20030319

AB Diseases such as BSE, CJD or scrapie are diagnosed in a subject by analyzing a sample of body fluid by mass spectrometry to det. the presence of a polypeptide marker of mol. wt. 3500 to 30000 where the polypeptide is present in different amts. in the body fluid of infected and non-infected subjects. The test sample may be adsorbed on a probe carrying an adsorbent material capable of binding the polypeptide. The material is e.g. a metal chelating group complexed with a metal ion. Kits for carrying out the diagnosis are also disclosed. The body fluid sample may be from humans or cattle.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 USPATFULL on STN
AN 2003:225768 USPATFULL
TI Diagnostic assay for transmissible ***spongiform*** encephalopathies
IN Hochstrasser, Denis Francois, Geneva, SWITZERLAND
Sanchez, Jean-Charles , Geneva, SWITZERLAND
Zimmermann, Catherine Gabrielle, Geneva, SWITZERLAND
Guillaume, Elisabeth, Annemasse, FRANCE
PI US 2003157580 A1 20030821
AI US 2002-238557 A1 20020910 (10)
RLI Continuation of Ser. No. WO 2001-EP2894, filed on 12 Mar 2001, UNKNOWN
PRAI GB 2000-5683 20000310
GB 2000-6064 20000314
DT Utility
FS APPLICATION
LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an

assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

L4 ANSWER 5 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2
AN 2004:60806 BIOSIS
DN PREV200400061254
TI A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease.
AU Guillaume, Elisabeth [Reprint Author]; Zimmermann, Catherine; Burkhard, Pierre R.; Hochstrasser, Denis F.; ***Sanchez, Jean-Charles***
CS Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, 24, Rue Micheli-du-Crest, 1211, Geneva 14, Switzerland
guillaum@dim.hcuge.ch
SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1495-1499. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004
AB The recent occurrence of the new variant of Creutzfeldt-Jakob disease (CJD), probably transmitted to humans by cattle affected by the bovine form of ***spongiform*** encephalopathy, has generated renewed interest in the clinical issues related to human ***spongiform*** encephalopathies. Using the current set of diagnostic tools, these rare but devastating conditions may be difficult to diagnose with accuracy before death. The objective of the present communication is to describe the discovery of a potential cerebrospinal fluid (CSF) and plasmatic marker of human transmissible ***spongiform*** encephalopathies. A preliminary two-dimensional electrophoresis approach highlighted a potential neurodegenerative disorder marker called the fatty acid binding protein, FABP. Its heart form, H-FABP, was investigated in a small group of CJD affected patients (n=8) by an immunoassay approach. The amount of FABP appeared to be significantly (pltoreq0.05) increased in all tested samples. H-FABP detection could therefore be helpful as a blood screening test for a pre-mortem diagnosis of the disease and also to prevent the risk of iatrogenic transmission of CJD through blood transfusion.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:677072 CAPLUS
DN 135:207875
TI Diagnostic assay for transmissible ***spongiform*** encephalopathies
IN Hochstrasser, Denis Francois; ***Sanchez, Jean-Charles*** ; Zimmermann, Catherine Gabrielle; Guillaume, Elisabeth
PA Universite de Geneve, Switz.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001067108	A2	20010913	WO 2001-EP2894	20010312
	WO 2001067108	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	GB 2360089	A1	20010912	GB 2000-5683	20000310
	CA 2402314	AA	20010913	CA 2001-2402314	20010312
	EP 1261875	A2	20021204	EP 2001-931527	20010312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003526788	T2	20030909	JP 2001-566030	20010312
	US 2003157580	A1	20030821	US 2002-238557	20020910
PRAI	GB 2000-5683	A	20000310		
	GB 2000-6064	A	20000314		
	WO 2001-EP2894	W	20010312		

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, esp. CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

L4 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 3
AN 1997:509954 BIOSIS
DN PREV199799809157
TI Elevation of apolipoprotein E in the CSF of cattle affected by BSE.
AU Hochstrasser, Denis F.; Frutiger, Severine; Wilkins, Marc R.; Hughes, Graham; ***Sanchez, Jean-Charles*** [Reprint author]
CS Clinical Chem. Lab., Geneva Univ. Hosp., 24 Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
SO FEBS Letters, (1997) Vol. 416, No. 2, pp. 161-163.
CODEN: FEBLAL. ISSN: 0014-5793.
DT Article
LA English
ED Entered STN: 10 Dec 1997
Last Updated on STN: 10 Dec 1997
AB The cerebrospinal fluid (CSF) of patients suffering from Creutzfeldt-Jakob disease (CJD) display two unique polypeptide chains by two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). In the absence of a well-defined ante-mortem diagnostic test for bovine ***spongiform*** encephalopathy (BSE), spinal fluid samples of eight normal cows and eight cows known to carry BSE by postmortem histological analysis were investigated to verify if equivalent polypeptides were present. Proteins with similar migration to human CJD polypeptides were not detected. But surprisingly, a cluster of polypeptide spots that was faint or not detected in normal bovine CSF samples was found to be elevated or massively increased in BSE CSF samples (more than 10-fold increase). These elevated polypeptide chains were identified as apolipoprotein E.

=> e guillaume elisabeth/au
E1 2 GUILLAUME E W/AU
E2 1 GUILLAUME EDOUARD/AU

```
E3          26 --> GUILLAUME ELISABETH/AU
E4           6     GUILLAUME EMILE/AU
E5           7     GUILLAUME EMILE A H/AU
E6           1     GUILLAUME EMILE ARMAND HENRI/AU
E7           1     GUILLAUME EMMANELLE/AU
E8           2     GUILLAUME EMMANUEL/AU
E9           2     GUILLAUME EMMANUELLE C/AU
E10          1     GUILLAUME EON JEAN/AU
E11          1     GUILLAUME ERRICK/AU
E12        200     GUILLAUME F/AU

=> s e3
L5          26 "GUILLAUME ELISABETH"/AU

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6          14 DUP REM L5 (12 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y


L6   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2005:134137  CAPLUS
DN   142:216620
TI   Use of antithrombin III, Apo C-I, Apo C-III, or serum amyloid A as
     diagnostic markers for stroke and immunological and SELDI-MS assays for
     the markers
IN     ***Guillaume, Elisabeth***  ; Sanchez, Jean-Charles; Hochstrasser, Denis
     Francois; Allard, Laure; Lescuyer, Pierre
PA   Universite De Geneve, Switz.
SO   Brit. UK Pat. Appl., 51 pp.
     CODEN: BAXXDU
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   GB 2404981           A1    20050216    GB 2003-19167            20030815
     WO 2005017523        A2    20050224    WO 2004-GB3512           20040816
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRAI GB 2003-19167        A     20030815
AB   A method is described for diagnosing stroke which comprises detg. concns.
     of either antithrombin III, apolipoprotein C-I (Apo C-I), Apo C-III, or
     serum amyloid A protein (SAA) in a patient's body fluid, preferably
     plasma.  The specific proteins are preferably detected using Surface
     Enhanced Laser Desorption Ionization (SELDI) Mass Spectroscopy (MS).
```

Proteins from body fluid are chromatog. absorbed to protein chip arrays for anal. by SELDI-MS. Alternatively the proteins may be detected using specific antibodies in immunochem. assays particularly using solid-phase antibody chips. Data indicate that Apo C-III, and serum amyloid A protein are differentially expressed in stroke patients compared to controls.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
AN 2004:722816 CAPLUS
DN 141:239284
TI Diagnostic method for transmissible spongiform encephalopathies
IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; ***Guillaume,*** *** Elisabeth***
PA Switz.
SO U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171026	A1	20040902	US 2003-695194	20031028
	GB 2379737	A1	20030319	GB 2001-21459	20010905
	WO 2003023406	A2	20030320	WO 2002-EP10063	20020903
	WO 2003023406	A3	20031127		
	WO 2003023406	C2	20040226		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	GB 2001-21459	A	20010905
	WO 2002-EP10063	A2	20020903
	GB 2002-25245	A	20021030
	GB 2003-6290	A	20030319

AB Transmissible spongiform encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000.

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:392701 CAPLUS
DN 140:371477
TI Diagnostic method for transmissible spongiform encephalopathies
IN Sanchez, Jean-Charles; Hochstrasser, Denis Francois; ***Guillaume,*** *** Elisabeth***
PA Proteome Sciences Plc., UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004040316	A2	20040513	WO 2003-GB4574	20031023
	WO 2004040316	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	GB 2002-25245	A	20021030
	GB 2003-6290	A	20030319

AB Transmissible spongiform encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000, but excluding the range of from 3500 to 30000. TSE can be diagnosed in a subject by detg. a test amt. of a polypeptide in a sample of body fluid, wherein the polypeptide is Cystatin C or a Hb, a Hb chain or a truncated chain or a fragment thereof which exhibits an immunol. reaction to an antibody to bovine Hb.

L6 ANSWER 4 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2
AN 2004:432942 BIOSIS
DN PREV200400431029
TI Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease.
AU Sanchez, Jean-Charles [Reprint Author]; ***Guillaume, Elisabeth*** ; Lescuyer, Pierre; Allard, Laure; Carrette, Odile; Scherl, Alex; Burgess, Jennifer; Corthals, Garry L.; Burkhard, Pierre R.; Hochstrasser, Denis F.
CS Biomed Proteom Res GrpCent Clin Chem Lab, Geneva Univ Hosp, 24 Rue Micheli Du Crest, CH-1211, Geneva, 14, Switzerland
sanchez@sim.hcuge.ch
SO Proteomics, (August 2004) Vol. 4, No. 8, pp. 2229-2233. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 10 Nov 2004
Last Updated on STN: 10 Nov 2004
AB The definite diagnosis of Creutzfeldt-Jakob disease (CJD), the most common form of human prion diseases, relies upon neuropathological data usually obtained at autopsy. In living patients, the diagnosis, based on suggestive clinical features and EEG abnormalities, can be aided by the detection of altered levels of isoforms of the 14-3-3 protein in the cerebrospinal fluid (CSF). However, the validity of this test has been recently challenged and the search for other, more reliable biomarkers for CJD remains highly desirable. The present study describes the identification of a new potential surrogate marker in the CSF of CJD-affected patients. A preliminary study employing surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) technology

highlighted a protein at 13.4 kDa in a small group (n = 8) of CJD-affected patients. Further analysis aimed at identifying this protein using cationic exchange chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed it to be cystatin C. Additional immunoblot assays confirmed that the level of cystatin C was significantly increased (p ltoreq 0.05) in all tested samples (n = 8). We conclude that the analysis of cystatin C levels in CSF could be useful as a pre-mortern indicator of the disease.

L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:657025 CAPLUS
DN 139:176362
TI Diagnostic method for stroke
IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; ***Guillaume,*** *** Elisabeth*** ; Allard, Laure
PA Universite De Geneve, Switz.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003069346	A2	20030821	WO 2003-EP1462	20030213
	WO 2003069346	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1476759	A2	20041117	EP 2003-739491	20030213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	GB 2002-3768	A	20020218		
	WO 2003-EP1462	W	20030213		

AB Stroke is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects, and has a mol. wt. in the range of from 3000 to 30000.

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:222395 CAPLUS
DN 138:262426
TI Diagnostic method for spongiform encephalopathy disease
IN ***Guillaume, Elisabeth*** ; Hochstrasser, Denis Francois; Sanchez, Jean-charles
PA Universite de Geneve, Switz.
SO Brit. UK Pat. Appl., 24 pp.
CODEN: BAXXDU
DT Patent

LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2379737	A1	20030319	GB 2001-21459	20010905
	WO 2003023406	A2	20030320	WO 2002-EP10063	20020903
	WO 2003023406	A3	20031127		
	WO 2003023406	C2	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1423703	A2	20040602	EP 2002-767478	20020903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005502882	T2	20050127	JP 2003-527426	20020903
	US 2004171026	A1	20040902	US 2003-695194	20031028
PRAI	GB 2001-21459	A	20010905		
	WO 2002-EP10063	W	20020903		
	GB 2002-25245	A	20021030		
	GB 2003-6290	A	20030319		

AB Diseases such as BSE, CJD or scrapie are diagnosed in a subject by analyzing a sample of body fluid by mass spectrometry to det. the presence of a polypeptide marker of mol. wt. 3500 to 30000 where the polypeptide is present in different amts. in the body fluid of infected and non-infected subjects. The test sample may be adsorbed on a probe carrying an adsorbent material capable of binding the polypeptide. The material is e.g. a metal chelating group complexed with a metal ion. Kits for carrying out the diagnosis are also disclosed. The body fluid sample may be from humans or cattle.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 14 USPATFULL on STN
AN 2003:225768 USPATFULL
TI Diagnostic assay for transmissible spongiform encephalopathies
IN Hochstrasser, Denis Francois, Geneva, SWITZERLAND
Sanchez, Jean-Charles, Geneva, SWITZERLAND
Zimmermann, Catherine Gabrielle, Geneva, SWITZERLAND
Guillaume, Elisabeth , Annemasse, FRANCE
PI US 2003157580 A1 20030821
AI US 2002-238557 A1 20020910 (10)
RLI Continuation of Ser. No. WO 2001-EP2894, filed on 12 Mar 2001, UNKNOWN
PRAI GB 2000-5683 20000310
GB 2000-6064 20000314
DT Utility
FS APPLICATION
LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)

LN.CNT 482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

L6 ANSWER 8 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 3
AN 2004:60813 BIOSIS
DN PREV200400061261
TI Proteomics application exercise of the Swiss Proteomics Society: Report of the SPS'02 session.
AU Binz, Pierre-Alain [Reprint Author]; Abdi, Fadi; Affolter, Michael; Allard, Laure; Barblan, Jachen; Bhardwaj, Sanjeev; Bienvenut, Willy V.; Bulet, Philippe; Burgess, Jennifer; Carrette, Odile; Corthals, Garry; Delalande, Francois; Diemer, Helene; Favreau, Philippe; Giuliano, Elia; Gueguen, Yannick; ***Guillaume, Elisabeth*** ; Hahner, Stephanie; Man, Petr; Michalet, Sophie; Neri, Dario; Noukakis, Dimitrios; Palagi, Patricia; Paroutaud, Pierre; Pimenta, Daniel Carvalho; Quadroni, Manfredo; Resemann, Anja; Richert, Sophie; Rybak, Jascha; Sanchez, Jean-Charles; Scherl, Alexander; Scheurer, Simone; Hufnagel, Ulrike Schweiger; Siethoff, Christoph; Suckau, Detlev; Van Dorsselaer, Alain; Redeker, Winfried Wagner; Walter, Nadia; Stocklin, Reto
CS Proteome Informatics Group, Swiss Institute of Bioinformatics, 1, Michel-Servet, CH-1211, Geneva, Switzerland
pierre-alain.binz@isb-sib.ch
SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1562-1566. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004
AB After the success of the mass spectrometry (MS) round table that was held at the first Swiss Proteomics Society congress (SPS'01) in Geneva, the SPS has organized a proteomics application exercise and allocated a full session at the SPS'02 congress. The main objective was to encourage the exchange of expertise in protein identification, with a focus on the use of mass spectrometry, and to create a bridge between the users' questions and the instrument providers' solutions. Two samples were sent to fifteen interested labs, including academic groups and MS hardware providers. Participants were asked to identify and partially characterize the samples. They consisted of a complex mixture of peptide/proteins (sample A) and an almost pure recombinant peptide carrying post-translational modifications (sample B). Sample A was an extract of snake venom from the species Bothrops jararaca. Sample B was a recombinant and modified peptide derived from the shrimp Penaeus vannamei penaeidin 3a. The eight labs that returned results reported the use of a wide range of MS instrumentation and techniques. They mentioned a variety of time and manpower allocations. The origin of sample A was generally identified together with a number of database protein entries. The difficulty of the sample identification lay in the incomplete knowledge of the Bothrops species genome sequence and is discussed. Sample B was generally and correctly identified as penaeidin. However, only one group reported the

full primary structure. Interestingly, the approaches were again varied and are discussed in the text.

L6 ANSWER 9 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 4
AN 2004:60806 BIOSIS
DN PREV200400061254
TI A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease.
AU ***Guillaume, Elisabeth*** [Reprint Author]; Zimmermann, Catherine; Burkhard, Pierre R.; Hochstrasser, Denis F.; Sanchez, Jean-Charles
CS Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, 24, Rue Micheli-du-Crest, 1211, Geneva 14, Switzerland
guillaum@dim.hcuge.ch
SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1495-1499. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004
AB The recent occurrence of the new variant of Creutzfeldt-Jakob disease (CJD), probably transmitted to humans by cattle affected by the bovine form of spongiform encephalopathy, has generated renewed interest in the clinical issues related to human spongiform encephalopathies. Using the current set of diagnostic tools, these rare but devastating conditions may be difficult to diagnose with accuracy before death. The objective of the present communication is to describe the discovery of a potential cerebrospinal fluid (CSF) and plasmatic marker of human transmissible spongiform encephalopathies. A preliminary two-dimensional electrophoresis approach highlighted a potential neurodegenerative disorder marker called the fatty acid binding protein, FABP. Its heart form, H-FABP, was investigated in a small group of CJD affected patients (n=8) by an immunoassay approach. The amount of FABP appeared to be significantly (pltoreq0.05) increased in all tested samples. H-FABP detection could therefore be helpful as a blood screening test for a pre-mortem diagnosis of the disease and also to prevent the risk of iatrogenic transmission of CJD through blood transfusion.

L6 ANSWER 10 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 5
AN 2003:512147 BIOSIS
DN PREV200300515495
TI Production of the antiviral proteins 2'5'oligoadenylate synthetase, PKR and Mx in interstitial cells and spermatogonia.
AU Melaine, Nathalie; Lienard, Marie-Odile; ***Guillaume, Elisabeth*** ; Ruffault, Annick; Dejucq-Rainsford, Nathalie; Jegou, Bernard [Reprint Author]
CS GERM-INSERM U.435, Universite de Rennes I, Campus de Beaulieu, 35 042, Rennes Cedex, Bretagne, France
bernard.jegou@rennes.inserm.fr
SO Journal of Reproductive Immunology, (June 2003) Vol. 59, No. 1, pp. 53-60. print.
CODEN: JRIMDR. ISSN: 0165-0378.
DT Article
LA English
ED Entered STN: 5 Nov 2003

Last Updated on STN: 5 Nov 2003

AB We report an in vitro analysis of the spatial pattern of production of three antiviral proteins (2'5'oligoadenylate synthetase, 2'5'AS; double-stranded RNA-activated protein kinase, PKR; and Mx protein, Mx) in the rat testis, in basal conditions and following stimulation with interferon (IFN) or Sendai virus. The two major constituents of interstitial tissue-Leydig cells and macrophages-constitutively produce 2'5' oligoadenylate synthetase (2'5'AS), PKR and Mx. Production of an isoform of 2'5'AS was induced following Leydig cells stimulation by the Sendai virus. The most immature germ cells, spermatogonia, were devoid of 2'5'AS whatever the type of stimulation, whereas IFN treatment induced Mx production and increased PKR production in this cell type. IFN stimulation strongly increased PKR production in all three cell types. This new set of data extends our previous investigations and demonstrates that the testis possesses an anti-viral defense system involving IFNs and IFN-induced anti-viral proteins.

L6 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:677072 CAPLUS
DN 135:207875
TI Diagnostic assay for transmissible spongiform encephalopathies
IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; Zimmermann, Catherine Gabrielle; ***Guillaume, Elisabeth***
PA Universite de Geneve, Switz.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001067108	A2	20010913	WO 2001-EP2894	20010312
	WO 2001067108	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	GB 2360089	A1	20010912	GB 2000-5683	20000310
	CA 2402314	AA	20010913	CA 2001-2402314	20010312
	EP 1261875	A2	20021204	EP 2001-931527	20010312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003526788	T2	20030909	JP 2001-566030	20010312
	US 2003157580	A1	20030821	US 2002-238557	20020910
PRAI	GB 2000-5683	A	20000310		
	GB 2000-6064	A	20000314		
	WO 2001-EP2894	W	20010312		

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, esp. CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific

to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

L6 ANSWER 12 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 6

AN 2001:452668 BIOSIS

DN PREV200100452668

TI Cellular distribution of translationally controlled tumor protein in rat and human testes.

AU ***Guillaume, Elisabeth*** ; Pineau, Charles [Reprint author]; Evrard, Bertrand; Dupaix, Alain; Moertz, Ejvind; Sanchez, Jean-Charles; Hochstrasser, Denis F.; Jegou, Bernard

CS GERM - INSERM U.435, Universite de Rennes I, Campus de Beaulieu, 35042, Rennes Cedex, Bretagne, France
charles.pineau@rennes.inserm.fr

SO Proteomics, (July, 2001) Vol. 1, No. 7, pp. 880-889. print.
ISSN: 1615-9853.

DT Article

LA English

ED Entered STN: 26 Sep 2001
Last Updated on STN: 22 Feb 2002

AB In a recent proteomic study we identified 53 spermatogonial proteins among which was the translationally controlled tumor protein (TCTP). This is a protein previously reported as being implicated in proliferation events in normal and tumoral tissues that had never previously been seen in the testis. The present study was aimed at establishing the complete cellular distribution of TCTP and its transcript and the ontogenetic expression of this gene within the testis. Using an immunohistochemistry technique, an intense TCTP signal was detected in gonocytes (the prespermatogonia) in the fetal rat testis and in spermatogonia within adult human and neonatal and adult rat testes. Meiotic spermatocytes and postmeiotic haploid spermatids were also strongly immunostained in a stage-dependent manner in human and rat testes. In addition, different levels of TCTP expression were also observed in the testicular somatic cells, with strong expression in Leydig cells and peritubular cells, and weak expression in Sertoli cells. Western and Northern blot analyses confirmed the presence of TCTP at all ages studied, with higher levels of RNA expression at 9 and 20 d postpartum, when spermatogonia and primary spermatocytes represent the highest proportion of germ cells: it was also confirmed that TCTP is present in all populations of isolated testicular cells. A transcript of 0.85 kb corresponding to TCTP, was expressed at all ages studied. This transcript was found to be expressed strongly in spermatogonia, somewhat less in isolated Leydig, resident macrophage, peritubular and Sertoli cells, weakly in the primary spermatocytes but not at all in spermatids. Interestingly, in the latter, a different transcript of 1.1 kb was present. The same 1.1 kb transcript appeared in testis extracts from 35 days postpartum onwards, corresponding to an age when spermatids accumulate within the tubules. Of note is that resident macrophages were found to express both the 0.85 and the 1.1 kb transcripts. We conclude that the strong expression of TCTP in spermatogonia makes it highly likely that the protein plays a significant role in spermatogenesis.

L6 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 7

AN 2002:25145 BIOSIS

DN PREV200200025145

TI Proteome analysis of rat spermatogonia: Reinvestigation of stathmin

spatio-temporal expression within the testis.

AU ***Guillaume, Elisabeth*** ; Evrard, Bertrand; Com, Emmanuelle; Moertz, Ejvind; Jegou, Bernard; Pineau, Charles [Reprint author]

CS GERM-INSERM U.435, Universite de Rennes I, Campus de Beaulieu, 35042, Rennes Cedex, Bretagne, France
charles.pineau@rennes.inserm.fr

SO Molecular Reproduction and Development, (December, 2001) Vol. 60, No. 4, pp. 439-445. print.
CODEN: MREDEE. ISSN: 1040-452X.

DT Article

LA English

ED Entered STN: 26 Dec 2001
Last Updated on STN: 25 Feb 2002

AB Stathmin is a protein known to be involved in various cell processes including cell proliferation and differentiation. It has already been described in the testis but its recent identification using a proteomic approach in mitotic spermatogenetic stem cells named spermatogonia (Guillaume et al., 2000) has lead us to reinvestigate its expression within the testis. Stathmin and its mRNAs were studied in isolated cells by Western and Northern blots and in situ using immunohistochemistry. We demonstrated that stathmin is indeed expressed in spermatogonia, and that it is also intensively expressed in the meiotic spermatocytes and in the first generations of spermatids. Furthermore, we showed aggregations of the protein in the cytoplasm of the later generations of spermatids preceding its elimination at the time of spermiation. Our Northern blots reveal the presence of two stathmin transcripts of 1.1 and 3.2 kb within the testis from the fetal stage onwards, in spermatogonia, spermatocytes, and spermatids. However, the 3.2 kb RNA transcript was barely detectable in the spermatids. Stathmin expression is known to be associated with microtubule dynamics. Therefore, its expression in the germ line is most probably related to the extremely complex structural cellular rearrangements occurring in germ cells during spermatogenesis. However, the exact role of stathmin and the reason of the existence of two transcripts in the male germ lineage awaits further investigation.

L6 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 8

AN 1998:353791 BIOSIS

DN PREV199800353791

TI Expression of interferons-alpha and -gamma in testicular interstitial tissue and spermatogonia of the rat.

AU Dejucq, Nathalie; Lienard, Marie-Odile; ***Guillaume, Elisabeth*** ; Dorval, Isabelle; Jegou, Bernard [Reprint author]

CS GERM-INSERM U-435, Univ. Rennes I, Campus Beaulieu, 35042 Rennes Cedex, Bretagne, France

SO Endocrinology, (July, 1998) Vol. 139, No. 7, pp. 3081-3087. print.
CODEN: ENDOAO. ISSN: 0013-7227.

DT Article

LA English

ED Entered STN: 13 Aug 1998
Last Updated on STN: 13 Aug 1998

AB The testis is divided into two compartments: the seminiferous tubules and the interstitial tissue. The latter essentially consists of the blood and lymphatic vessels, testosterone-producing Leydig cells, and testicular macrophages. In the exploration of the testicular antiviral defense system, we initially searched for interferon (IFN) production by the seminiferous tubule cells. The site of virus entry into the testis is

probably the interstitial compartment; thus, it is important to know whether and how the cells in this compartment are protected against viral infection. In addition, as germ cell precursors (spermatogonia) are only partially protected by the blood-testis barrier, it was important to explore the antiviral capability of these cells. In this study we searched for IFN production by Leydig cells, testicular macrophages, and spermatogonia after exposure to Sendai virus. We also investigated the effect of viral exposure on testosterone production by Leydig cells. Our results show that spermatogonia do not constitutively express IFNs and give a very poor response to the virus. In contrast, testicular macrophages constitutively produced type I IFNs, and this production was markedly stimulated by Sendai virus. Leydig cells produced twice as much type I IFNs as testicular macrophages after viral exposure, and they were the only cells producing both IFNalpha and -gamma, with these IFNs being dramatically induced/increased in response to exposure to the virus. Furthermore, incubation of Leydig cells with the Sendai virus stimulated testosterone production. In conclusion, this study further establishes the topography of IFN expression within the testis. This allows us to hypothesize that the potential antiviral system represented by Leydig cells and, to a lesser extent, by macrophages plays a key role in protecting both androgen production and spermatogenesis.

```
=> s diagnos? and (transmissible spongiform encephalo?)
L7        1688 DIAGNOS? AND (TRANSMISSIBLE SPONGIFORM ENCEPHALO?)

=> s l7 and spectrometry
L8         261 L7 AND SPECTROMETRY

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9          258 DUP REM L8 (3 DUPLICATES REMOVED)

=> s l9 and polypeptide?
L10        242 L9 AND POLYPEPTIDE?

=> s l10 and (molecular weight)
L11        227 L10 AND (MOLECULAR WEIGHT)

<------User Break------>

SEARCH ENDED BY USER
SEARCH ENDED BY USER

=> s l11 and ((cerebrospinal fluid)or CSF or (body fluid?) or plasma or serum or
blood or tears or urine or saliva)
L12        226 L11 AND ((CEREBROSPINAL FLUID) OR CSF OR (BODY FLUID?) OR PLASMA
                OR SERUM OR BLOOD OR TEARS OR URINE OR SALIVA)

=> s l12 and (diagnos?/ab or diagnos?/ti)
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
L13        212 L12 AND (DIAGNOS?/AB OR DIAGNOS?/TI)

=> s l13 and (spectrometr?/ab or spectrometr?/ti)
'AB' IS NOT A VALID FIELD CODE
```

```
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
L14          1 L13 AND (SPECTROMETR?/AB OR SPECTROMETR?/TI)

=> d

L14  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:722816  CAPLUS
DN   141:239284
TI     ***Diagnostic***   method for   ***transmissible***      ***spongiform***
       ***encephalopathies***
IN   Hochstrasser, Denis Francois; Sanchez, Jean-Charles; Guillaume, Elisabeth
PA   Switz.
SO   U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   US 2004171026         A1    20040902    US 2003-695194           20031028
     GB 2379737            A1    20030319    GB 2001-21459            20010905
     WO 2003023406         A2    20030320    WO 2002-EP10063          20020903
     WO 2003023406         A3    20031127
     WO 2003023406         C2    20040226
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2001-21459         A     20010905
     WO 2002-EP10063       A2    20020903
     GB 2002-25245         A     20021030
     GB 2003-6290          A     20030319


=> s l13 and (mass spectrometry)
L15        212 L13 AND (MASS SPECTROMETRY)

=> s l15 and (chip array?)
L16        154 L15 AND (CHIP ARRAY?)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 154 ANSWERS - CONTINUE? Y/(N):y

L16  ANSWER 1 OF 154  USPATFULL on STN
AN     2005:75247  USPATFULL
TI     69583 and 85924 Novel human protein kinase family members and uses
       therefor
IN     Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
       Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PI     US 2005064544      A1   20050324
```

AI US 2004-490592 A1 20040323 (10)
WO 2002-US34037 20021024
PRAI US 2001-338690P 20011024 (60)
DT Utility
FS APPLICATION
LREP Jean M Silveri, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 6620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 69583 and 85924 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69583 or 85924 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69583 or 85924 gene has been introduced or disrupted. The invention still further provides isolated 69583 or 85924 proteins, fusion proteins, antigenic peptides and anti-69583 or -85924 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 2 OF 154 USPATFULL on STN
AN 2005:23294 USPATFULL
TI Novel human membrane-associated protein and cell surface protein family members
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A.J., Ashland, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2005019838 A1 20050127
AI US 2004-860779 A1 20040603 (10)
RLI Continuation of Ser. No. US 2002-162435, filed on 4 Jun 2002, PENDING Continuation-in-part of Ser. No. US 2001-836499, filed on 17 Apr 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US12420, filed on 17 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-891008, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US19963, filed on 25 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-860868, filed on 18 May 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US16013, filed on 18 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-886429, filed on 21 Jun 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US20055, filed on 21 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2002-41406, filed on 8 Jan 2002, ABANDONED Continuation-in-part of Ser. No. WO 2002-US275, filed on 8 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2001-934268, filed on 21 Aug 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US41811, filed on 21 Aug 2001, PENDING
PRAI US 2000-197507P 20000418 (60)
US 2000-214220P 20000623 (60)
US 2000-205674P 20000519 (60)
US 2000-213963P 20000623 (60)

US 2001-260286P 20010108 (60)
US 2000-226612P 20000821 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 30445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid molecules, which encode novel human membrane-associated protein family members, and human cell surface protein family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or disrupted. The invention still further provides isolated 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins, antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 3 OF 154 USPATFULL on STN
AN 2004:327379 USPATFULL
TI 32544, Novel human phospholipase C and uses thereof
IN Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004259199 A1 20041223
AI US 2004-784089 A1 20040220 (10)
RLI Division of Ser. No. US 2001-927112, filed on 10 Aug 2001, PENDING
PRAI US 2000-246808P 20001108 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 5297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 4 OF 154 USPATFULL on STN

AN 2004:314570 USPATFULL
TI 47153, A HUMAN GLYCOSYLTRANSFERASE FAMILY MEMBER AND USES THEREFOR
IN Meyers, Rachel, Newton, MA, UNITED STATES
Rosenfeld, Julie Beth, Sharon, MA, UNITED STATES
PI US 2004248242 A1 20041209
US 6849437 B2 20050201
AI US 2002-113709 A1 20020328 (10)
PRAI US 2001-279647P 20010328 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47153 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47153 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47153 gene has been introduced or disrupted. The invention still further provides isolated 47153 proteins, fusion proteins, antigenic peptides and anti-47153 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 5 OF 154 USPATFULL on STN
AN 2004:314488 USPATFULL
TI Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and uses therefor
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
Curtis, Rory A.J., Ashland, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Hodge, Martin R., Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004248160 A1 20041209
AI US 2004-782695 A1 20040219 (10)
RLI Continuation-in-part of Ser. No. US 2001-7399, filed on 5 Nov 2001, ABANDONED Continuation of Ser. No. US 1999-390039, filed on 3 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-146416, filed on 3 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-103458, filed on 22 Mar 2002, ABANDONED Continuation of Ser. No. US 2000-544797, filed on 7 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2001-945254, filed on 31 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-945301, filed on 31 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-24036, filed on 17 Dec 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-192440, filed on 10 Jul 2002, ABANDONED
PRAI US 2000-229829P 20000831 (60)
US 2000-229301P 20000901 (60)
US 2000-258222P 20001222 (60)
US 2001-341953P 20011219 (60)

US 2001-304243P 20010710 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 27443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 6 OF 154 USPATFULL on STN
AN 2004:274256 USPATFULL
TI Novel human hydrolase family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2004214758 A1 20041028
AI US 2002-193452 A1 20020711 (10)
RLI Continuation-in-part of Ser. No. US 2001-816664, filed on 23 Mar 2001, ABANDONED
PRAI US 2000-191973P 20000324 (60)
US 2000-199559P 20000425 (60)
US 2000-206036P 20000522 (60)
US 2000-205442P 20000519 (60)
US 2000-209949P 20000606 (60)
US 2000-214948P 20000629 (60)
US 2000-220008P 20000721 (60)
US 2000-220040P 20000721 (60)
US 2000-226774P 20000821 (60)
US 2000-235033P 20000925 (60)
US 2000-238170P 20001005 (60)
US 2001-267054P 20010207 (60)
US 2000-213688P 20000623 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 62 Drawing Page(s)
LN.CNT 68657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated

26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, and 46508 nucleic acid molecules, which encode novel human hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 gene has been introduced or disrupted. The invention still further provides isolated 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 proteins, fusion proteins, antigenic peptides and anti-26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 7 OF 154 USPATFULL on STN
AN 2004:171926 USPATFULL
TI Novel human enzyme family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandria, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, 02139 (U.S. corporation)
PI US 2004132087 A1 20040708
AI US 2004-776871 A1 20040211 (10)
RLI Continuation of Ser. No. US 2002-175696, filed on 20 Jun 2002, PENDING Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-823901, filed on 30 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US10720, filed on 2 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-862658, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US16380, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-882837, filed on 15 Jun 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US19319, filed on 15 Jun 2001, PENDING
PRAI US 2001-266140P 20010202 (60)
US 2000-193920P 20000331 (60)
US 2000-205675P 20000519 (60)
US 2000-211727P 20000615 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 21375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors

containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 8 OF 154 USPATFULL on STN
AN 2004:158550 USPATFULL
TI Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Cook, William James, Hanover, NH, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Weich, Nadine S., Brookline, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004121349 A1 20040624
AI US 2003-391364 A1 20030318 (10)
RLI Continuation-in-part of Ser. No. US 2001-950370, filed on 10 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-294039, filed on 13 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-266035, filed on 7 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2000-717926, filed on 21 Nov 2000, GRANTED, Pat. No. US 6569657 Continuation-in-part of Ser. No. US 2002-268036, filed on 9 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2001-922138, filed on 3 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-945327, filed on 31 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2002-163316, filed on 5 Jun 2002, PENDING Continuation-in-part of Ser. No. US 2002-103377, filed on 21 Mar 2002, PENDING
PRAI US 2000-231084P 20000908 (60)
US 2001-338587P 20011113 (60)
US 2001-328198P 20011009 (60)
US 2000-214707P 20000627 (60)
US 2001-327820P 20011009 (60)
US 2000-229299P 20000901 (60)
US 2000-229425P 20000831 (60)
US 2001-297863P 20010613 (60)
US 2001-278347P 20010323 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577

nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 9 OF 154 USPATFULL on STN
AN 2004:114083 USPATFULL
TI 53010, a novel human carboxylesterase family member and uses thereof
IN Curtis, Rory A. J., Southborough, MA, UNITED STATES
Silos-Santiago, Immaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004086922 A1 20040506
AI US 2003-674636 A1 20030929 (10)
RLI Division of Ser. No. US 2001-23515, filed on 18 Dec 2001, GRANTED, Pat. No. US 6664091
PRAI US 2000-256369P 20001218 (60)
US 2001-279508P 20010328 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5079
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 53010 nucleic acid molecules, which encode novel carboxylesterase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53010 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53010 gene has been introduced or disrupted. The invention still further provides isolated 53010 proteins, fusion proteins, antigenic peptides and anti-53010 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 10 OF 154 USPATFULL on STN
AN 2004:114082 USPATFULL
TI 57242, a novel human G protein-coupled receptor family member and uses therefor
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Gimeno, Ruth, Wellesley, MA, UNITED STATES
White, David, Braintree, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004086921 A1 20040506
AI US 2003-665956 A1 20030918 (10)
RLI Continuation of Ser. No. US 2001-942374, filed on 29 Aug 2001, ABANDONED
PRAI US 2000-228409P 20000829 (60)
DT Utility
FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., Intellectual Property Department, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 104
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4729
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for the ***diagnosis*** and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, hyperlipidemia, overweight anorexia, or cachexia. The invention provides isolated nucleic acids molecules, designated 57242 nucleic acid molecules, which encode novel G protein-coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57242 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57242 gene has been introduced or disrupted. The invention still further provides isolated 57242 proteins, fusion proteins, antigenic peptides and anti-57242 antibodies. Methods of use of the provided 57242 compositions for screening, ***diagnostic*** and therapeutic methods in connection with metabolic disorders are also disclosed.

L16 ANSWER 11 OF 154 USPATFULL on STN
AN 2004:109094 USPATFULL
TI 18431 and 32374, novel human protein kinase family members and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Silos-Santiago, Immaculada, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004083496 A1 20040429
AI US 2003-678786 A1 20031003 (10)
RLI Continuation of Ser. No. US 2001-916790, filed on 27 Jul 2001, ABANDONED
PRAI US 2000-221543P 20000728 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 6026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 12 OF 154 USPATFULL on STN
AN 2004:107607 USPATFULL

TI 47174, a novel human glycosyltransferase and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004082007 A1 20040429
AI US 2003-713345 A1 20031114 (10)
RLI Division of Ser. No. US 2001-973457, filed on 9 Oct 2001, GRANTED, Pat. No. US 6703230
PRAI US 2000-238849P 20001006 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** neurological disorders are disclosed.

L16 ANSWER 13 OF 154 USPATFULL on STN
AN 2004:76577 USPATFULL
TI Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004058355 A1 20040325
AI US 2003-423543 A1 20030425 (10)
RLI Continuation-in-part of Ser. No. US 2002-278036, filed on 22 Oct 2002, PENDING Continuation of Ser. No. US 2000-711216, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2001-12055, filed on 13 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-3690, filed on 15 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-797039, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US

2002-217168, filed on 12 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2001-929218, filed on 14 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-963159, filed on 25 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-121911, filed on 12 Apr 2002, GRANTED, Pat. No. US 6607892 Division of Ser. No. US 1999-412210, filed on 5 Oct 1999, GRANTED, Pat. No. US 6403358 Continuation-in-part of Ser. No. US 2002-105989, filed on 25 Mar 2002, PENDING Continuation of Ser. No. US 1999-392189, filed on 9 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2003-336153, filed on 3 Jan 2003, PENDING Continuation of Ser. No. US 2001-845044, filed on 27 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-928531, filed on 13 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-920346, filed on 31 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-8016, filed on 8 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-909743, filed on 20 Jul 2001, PENDING Division of Ser. No. US 1999-448076, filed on 23 Nov 1999, GRANTED, Pat. No. US 6300092 Continuation-in-part of Ser. No. US 1999-276400, filed on 25 Mar 1999, GRANTED, Pat. No. US 6140056 Continuation-in-part of Ser. No. US 2003-336489, filed on 2 Jan 2003, PENDING Continuation of Ser. No. US 2000-608921, filed on 30 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1998-163821, filed on 30 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-60763, filed on 30 Jan 2002, ABANDONED Continuation of Ser. No. US 1999-365162, filed on 30 Jul 1999, ABANDONED

PRAI US 2000-205447P 20000519 (60)
US 2000-248325P 20001114 (60)
US 2000-248893P 20001115 (60)
US 2000-186061P 20000229 (60)
US 2001-312539P 20010815 (60)
US 2000-257511P 20001222 (60)
US 2000-234922P 20000925 (60)
US 2000-200688P 20000428 (60)
US 2000-235035P 20000925 (60)
US 2000-221925P 20000731 (60)
US 2001-260166P 20010105 (60)
US 2000-246669P 20001108 (60)
US 1999-117580P 19990127 (60)

DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14751
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529,

26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 14 OF 154 USPATFULL on STN
AN 2004:69999 USPATFULL
TI 23430, a novel human ubiquitin hydrolase family member and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2004053226 A1 20040318
AI US 2001-905301 A1 20010713 (9)
PRAI US 2000-218245P 20000714 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 23430 nucleic acid molecules, which encode novel ubiquitin hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23430 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23430 gene has been introduced or disrupted. The invention still further provides isolated 23430 proteins, fusion proteins, antigenic peptides and anti-23430 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 15 OF 154 USPATFULL on STN
AN 2004:44517 USPATFULL
TI Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004033509 A1 20040219
AI US 2003-377097 A1 20030228 (10)
RLI Continuation-in-part of Ser. No. US 2001-910150, filed on 18 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-251507, filed on 20 Sep 2002, PENDING
PRAI US 2000-219028P 20000718 (60)
DT Utility
FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN:CNT 15960
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 16 OF 154 USPATFULL on STN
AN 2004:27065 USPATFULL
TI 25934, a novel fatty acid desaturase and uses therefor
IN Logan, Thomas Joseph, Needham, MA, United States
Glucksmann, Maria Alexandra, Lexington, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6686185 B1 20040203
AI US 2000-723806 20001128 (9)
PRAI US 2000-187455P 20000307 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Slobodyansky, Elizabeth
LREP Millennium Pharmaceuticals Inc.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 4706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25934 nucleic acid molecules, which encode a novel desaturase family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25934 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25934 gene has been introduced or disrupted. The invention still further provides isolated 25934 proteins, fusion proteins, antigenic peptides and anti-25934 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods for modulating fatty

acid metabolism utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** cardiovascular disorders, such atherosclerosis, hypertriglyceridemia, hypercholesterolemia, and hyperlipidemia, are disclosed.

L16 ANSWER 17 OF 154 USPATFULL on STN
AN 2004:12981 USPATFULL
TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
IN Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004009501 A1 20040115
US 2004157221 A9 20040812
AI US 2003-377072 A1 20030227 (10)
RLI Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED
PRAI US 2000-215370P 20000629 (60)
US 2000-187455P 20000307 (60)
US 2000-199801P 20000426 (60)
US 2000-205508P 20000519 (60)
US 2000-213688P 20000623 (60)
US 2000-218675P 20000717 (60)
US 2000-250932P 20001130 (60)
US 2000-226504P 20000821 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934,

26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 18 OF 154 USPATFULL on STN
AN 2004:7430 USPATFULL
TI Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Curtis, Rory A. J., Ashland, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Weich, Nadine S., Brookline, MA, UNITED STATES
Olandt, Peter J., Buffalo, NY, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004005664 A1 20040108
AI US 2003-410764 A1 20030410 (10)
RLI Continuation-in-part of Ser. No. US 2001-924358, filed on 6 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2003-350553, filed on 24 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-966614, filed on 27 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2002-281094, filed on 25 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-76535, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-860352, filed on 17 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-593927, filed on 15 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-226410, filed on 23 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2001-997816, filed on 29 Nov 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-686673, filed on 11 Oct 2000, PENDING
PRAI US 2000-229300P 20000901 (60)
US 2002-351572P 20020124 (60)
US 2000-238054P 20001005 (60)
US 2001-347815P 20011029 (60)
US 2001-269440P 20010216 (60)
US 2000-205301P 20000519 (60)
US 2000-199391P 20000425 (60)
US 2001-314884P 20010824 (60)
US 2000-250186P 20001130 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 17049
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764,

62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 19 OF 154 USPATFULL on STN
AN 2004:7390 USPATFULL
TI 84573, a human protein kinase family member and uses therefor
IN Tayber, Olga, Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004005624 A1 20040108
AI US 2003-460545 A1 20030612 (10)
PRAI US 2002-388031P 20020612 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE, MA, 02139
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 84573 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 84573 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 84573 gene has been introduced or disrupted. The invention still further provides isolated 84573 proteins, fusion proteins, antigenic peptides and anti-84573 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 20 OF 154 USPATFULL on STN
AN 2003:330125 USPATFULL
TI Novel human ion channel and transporter family members
IN Curtis, Rory A. J., Framingham, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
Gu, Wei, Brookline, MA, UNITED STATES
PI US 2003232336 A1 20031218
AI US 2002-162102 A1 20020604 (10)
RLI Continuation-in-part of Ser. No. US 2001-875321, filed on 6 Jun 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US18340, filed on 6 Jun 2001, PENDING
PRAI WO 2001-US18340 20010606
WO 2001-US18398 20010605
WO 2001-US18247 20010605
WO 2001-US25474 20010815
WO 2001-US26096 20010821

WO 2002-US9728 20020328
US 2001-290288P 20010511 (60)
US 2001-279281P 20010328 (60)
US 2000-226770P 20000821 (60)
US 2000-227068P 20000822 (60)
US 2000-209845P 20000606 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 40 Drawing Page(s)
LN.CNT 38135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, and 8105 nucleic acid molecules, which encode novel human calcium channel family members, human sodium ion channel family members, human potassium channel family members, human sodium-sugar symporter family members, human ABC transporter family members, human cation family members, and human sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 gene has been introduced or disrupted. The invention still further provides isolated 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 proteins, fusion proteins, antigenic peptides and anti-52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 21 OF 154 USPATFULL on STN
AN 2003:318632 USPATFULL
TI Novel human transferase family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Hunter, John J., Somerville, MA, UNITED STATES
PI US 2003224376 A1 20031204
AI US 2002-184648 A1 20020627 (10)
RLI Continuation-in-part of Ser. No. US 2001-815028, filed on 22 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-801220, filed on 7 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-816714, filed on 23 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-844948, filed on 27 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-861164, filed on 18 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-883060, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-962678, filed on 25 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-973457, filed on 9 Oct

2001, PENDING Continuation-in-part of Ser. No. US 2002-72285, filed on 8 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-817910, filed on 26 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-842528, filed on 25 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-882836, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-882872, filed on 15 Jun 2001, ABANDONED

PRAI WO 2001-US9358 20010322
WO 2001-US7269 20010307
WO 2001-US9468 20010323
WO 2001-US13805 20010427
WO 2001-US16292 20010518
WO 2001-US19138 20010615
WO 2001-US29963 20010925
WO 2002-US3736 20020208
WO 2001-US9633 20010326
WO 2001-US40607 20010425
WO 2001-US19543 20010615
WO 2001-US19153 20010615
US 2000-191964P 20000324 (60)
US 2000-187456P 20000307 (60)
US 2000-191865P 20000324 (60)
US 2000-200604P 20000428 (60)
US 2000-205408P 20000519 (60)
US 2000-212079P 20000615 (60)
US 2000-235044P 20000925 (60)
US 2000-238849P 20001006 (60)
US 2001-267494P 20010208 (60)
US 2000-192092P 20000324 (60)
US 2000-199500P 20000425 (60)
US 2000-211730P 20000615 (60)
US 2000-212077P 20000615 (60)

DT Utility

FS APPLICATION

LREP Theodore R. Allen, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 125 Drawing Page(s)

LN.CNT 66695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 22 OF 154 USPATFULL on STN
AN 2003:312209 USPATFULL
TI Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
Curtis, Rory A.J., Ashland, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003219806 A1 20031127
AI US 2003-391399 A1 20030318 (10)
RLI Continuation-in-part of Ser. No. US 2001-789481, filed on 20 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-634669, filed on 8 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-583373, filed on 31 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-510706, filed on 22 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-309804, filed on 4 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-94214, filed on 8 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-828035, filed on 6 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-891762, filed on 26 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2002-245121, filed on 17 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-95139, filed on 11 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-957683, filed on 19 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-942447, filed on 29 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-62937, filed on 31 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2002-255532, filed on 26 Sep 2002, PENDING
PRAI US 2001-336936P 20011204 (60)
US 2001-275078P 20010312 (60)
US 2000-195734P 20000407 (60)
US 2000-214176P 20000626 (60)
US 2001-322983P 20010917 (60)
US 2001-275172P 20010312 (60)
US 2000-233537P 20000919 (60)
US 2000-229036P 20000831 (60)
US 2001-267076P 20010201 (60)
US 2001-325854P 20010927 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18607, 15603,

69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 gene has been introduced or disrupted. The invention still further provides isolated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 proteins, fusion proteins, antigenic peptides and anti-18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 23 OF 154 USPATFULL on STN
AN 2003:306426 USPATFULL
TI Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003215860 A1 20031120
AI US 2003-407079 A1 20030403 (10)
RLI Continuation-in-part of Ser. No. US 2002-226102, filed on 22 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225094, filed on 21 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-272417, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 2000-715790, filed on 17 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-282837, filed on 29 Oct 2002, PENDING Continuation of Ser. No. US 2001-796338, filed on 28 Feb 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-863200, filed on 22 May 2001, ABANDONED
PRAI US 2001-314041P 20010822 (60)
US 2001-314185P 20010822 (60)
US 2000-191845P 20000324 (60)
US 2000-186059P 20000229 (60)
US 2000-206019P 20000522 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the

invention are also provided.

L16 ANSWER 24 OF 154 USPATFULL on STN
AN 2003:265842 USPATFULL
TI 58224, a novel helicase family member and uses therefor
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PI US 2003186859 A1 20031002
AI US 2001-861165 A1 20010518 (9)
PRAI US 2000-205442P 20000519 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 58224 nucleic acid molecules, which encode novel helicase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58224 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 58224 gene has been introduced or disrupted. The invention still further provides isolated 58224 proteins, fusion proteins, antigenic peptides and anti-58224 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 25 OF 154 USPATFULL on STN
AN 2003:257879 USPATFULL
TI Novel human protein kinase, phosphatase, and protease family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Curtis; Rory A. J., Framingham, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
PI US 2003180930 A1 20030925
AI US 2002-170789 A1 20020613 (10)
RLI Continuation-in-part of Ser. No. US 2001-797039, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-882166, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-934406, filed on 21 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-801267, filed on 6 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-829671, filed on 10 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-961721, filed on 24 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-45367, filed on 7 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-801275, filed on 6 Mar 2001, PENDING
PRAI WO 2001-US6525 20010228
WO 2001-US19269 20010615
WO 2001-US26052 20010821
WO 2001-US16549 20010521
WO 2001-US7138 20010305
WO 2001-US40483 20010411

WO 2001-US29904 20010924
WO 2001-US7074 20010305
US 2000-186061P 20000229 (60)
US 2000-212078P 20000615 (60)
US 2000-226740P 20000821 (60)
US 2000-205508P 20000519 (60)
US 2000-187454P 20000307 (60)
US 2000-197508P 20000418 (60)
US 2000-235023P 20000925 (60)
US 2000-246561P 20001107 (60)
US 2000-187420P 20000307 (60)

DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 62 Drawing Page(s)
LN.CNT 45159
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 26 OF 154 USPATFULL on STN
AN 2003:251541 USPATFULL
TI 55562 and 21617, novel human proteins and methods of use thereof
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
PI US 2003176330 A1 20030918
AI US 2001-23617 A1 20011218 (10)
PRAI US 2000-256249P 20001218 (60)
US 2000-256405P 20001218 (60)

DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 6105
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21617 and 55562 nucleic acid molecules, which encode novel dehydrogenase or tetratricopeptide repeat members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21617 or 55562 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21617 or 55562 gene has been introduced or disrupted. The invention still further provides isolated 21617 or 55562 proteins, fusion proteins, antigenic peptides and anti-21617 or 55562 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 27 OF 154 USPATFULL on STN
AN 2003:238736 USPATFULL
TI 14715, a human fringe family member and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Anderson, Karen L., Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166894 A1 20030904
AI US 2002-141604 A1 20020508 (10)
PRAI US 2001-289894P 20010509 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 14715 nucleic acid molecules, which encode novel fringe family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14715 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14715 gene has been introduced or disrupted. The invention still further provides isolated 14715 proteins, fusion proteins, antigenic peptides and anti-14715 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 28 OF 154 USPATFULL on STN
AN 2003:238734 USPATFULL
TI 58566, a human anion exchanger family member and uses therefor
IN Curtis, Rory A.J., Farmingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166892 A1 20030904
AI US 2002-128202 A1 20020423 (10)
PRAI US 2001-286029P 20010424 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)

LN.CNT 5263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 58566 nucleic acid molecules, which encode novel anion exchanger family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58566 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 58566 gene has been introduced or disrupted. The invention still further provides isolated 58566 proteins, fusion proteins, antigenic peptides and anti-58566 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 29 OF 154 USPATFULL on STN
AN 2003:238727 USPATFULL
TI 52948, a human ABC transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166885 A1 20030904
AI US 2002-79087 A1 20020220 (10)
PRAI US 2001-272958P 20010302 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 52948 nucleic acid molecules, which encode novel ABC transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52948 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52948 gene has been introduced or disrupted. The invention still further provides isolated 52948 proteins, fusion proteins, antigenic peptides and anti-52948 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 30 OF 154 USPATFULL on STN
AN 2003:238087 USPATFULL
TI 57316 and 33338, human ubiquitin carboxyl terminal hydrolases and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166244 A1 20030904
AI US 2002-98108 A1 20020313 (10)
PRAI US 2001-276395P 20010316 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 57316 or 33338 nucleic acid molecules, which encode ubiquitin carboxyl terminal hydrolase proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57316 or 33338 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 57316 or 33338 gene has been introduced or disrupted. The invention still further provides isolated 57316 or 33338 proteins, fusion proteins, antigenic peptides and anti-57316 or 33338 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 31 OF 154 USPATFULL on STN
AN 2003:238067 USPATFULL
TI 18232, a novel dual specificity phosphatase and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., a Delaware corporation (U.S. corporation)
PI US 2003166224 A1 20030904
AI US 2002-165272 A1 20020607 (10)
RLI Continuation of Ser. No. US 2000-704139, filed on 1 Nov 2000, GRANTED, Pat. No. US 6420153
PRAI US 2000-185772P 20000229 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

L16 ANSWER 32 OF 154 USPATFULL on STN
AN 2003:238065 USPATFULL
TI 39267, human kinase family members and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (non-U.S. corporation)
PI US 2003166222 A1 20030904
AI US 2003-335687 A1 20030102 (10)
PRAI US 2002-345773P 20020102 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL. Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 7069
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 39267 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 39267 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 39267 gene has been introduced or disrupted. The invention still further provides isolated 39267 proteins, fusion proteins, antigenic peptides and anti-39267 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 33 OF 154 USPATFULL on STN
AN 2003:237903 USPATFULL
TI 58297, an amino acid transporter and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166060 A1 20030904
AI US 2002-44901 A1 20020110 (10)
PRAI US 2001-262515P 20010118 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5115
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 58297 nucleic acid molecules, which encode amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58297 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 58297 gene has been introduced or disrupted. The invention still further provides isolated 58297 proteins, fusion proteins, antigenic peptides and anti-58297 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 34 OF 154 USPATFULL on STN
AN 2003:237902 USPATFULL

TI 54498, an amino acid transporter and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166059 A1 20030904
AI US 2002-44897 A1 20020110 (10)
PRAI US 2001-261408P 20010112 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 54498 nucleic acid molecules, which encode amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 54498 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 54498 gene has been introduced or disrupted. The invention still further provides isolated 54498 proteins, fusion proteins, antigenic peptides and anti-54498 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 35 OF 154 USPATFULL on STN
AN 2003:237726 USPATFULL
TI 27091, a phospholipid transporting ATPase molecule and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003165883 A1 20030904
AI US 2002-122067 A1 20020412 (10)
PRAI US 2001-283434P 20010412 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 27091 nucleic acid molecules, which encode novel ATPase/PLTR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27091 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27091 gene has been introduced or disrupted. The invention still further provides isolated 27091 proteins, fusion proteins, antigenic peptides and anti-27091 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 36 OF 154 USPATFULL on STN
AN 2003:231996 USPATFULL

TI Methods of using 69039, a novel human Na/Ca exchanger family member
IN Carroll, Joseph M., Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003162196 A1 20030828
AI US 2002-256537 A1 20020927 (10)
PRAI US 2001-325737P 20010928 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated nucleic acids molecules, designated 69039 nucleic acid molecules, which encode novel Na.sup.+/Ca.sup.2+ exchanger members, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69039 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69039 gene has been introduced or disrupted. Isolated 69039 proteins, fusion proteins, antigenic peptides and anti-69039 antibodies are also disclosed. The invention further provides methods of treating, preventing and ***diagnosing*** hematopoietic and neurological disorders.

L16 ANSWER 37 OF 154 USPATFULL on STN
AN 2003:213643 USPATFULL
TI 65499 and 58875, novel seven transmembrane receptors and uses thereof
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
PI US 2003148281 A1 20030807
AI US 2001-971269 A1 20011003 (9)
PRAI US 2000-237700P 20001005 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 5168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 65499 and 58875 nucleic acid molecules, which encode novel seven transmembrane domain (7TM) receptors, e.g., G-protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65499 or 58875 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 65499 or 58875 gene has been introduced or disrupted. The invention still further provides isolated 65499 or 58875 proteins, fusion proteins, antigenic peptides and anti-65499 or 58875 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 38 OF 154 USPATFULL on STN
AN 2003:200949 USPATFULL

TI 80091, a novel human ubiquitin carboxy-terminal hydrolase family member and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PI US 2003138934 A1 20030724
AI US 2002-71275 A1 20020207 (10)
PRAI US 2001-267054P 20010207 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 80091 nucleic acid molecules, which encode novel ubiquitin carboxy-terminal hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80091 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80091 gene has been introduced or disrupted. The invention still further provides isolated 80091 proteins, fusion proteins, antigenic peptides and anti-80091 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 39 OF 154 USPATFULL on STN
AN 2003:200905 USPATFULL
TI Novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2003138890 A1 20030724
AI US 2002-145586 A1 20020514 (10)
RLI Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb 2001, PENDING
PRAI WO 2001-US6057 20010223
WO 2001-US23152 20010723
WO 2001-US40476 20010409
WO 2001-US7139 20010305
WO 2001-US19544 20010615
WO 2001-US29967 20010925
WO 2001-US9470 20010323
WO 2001-US10380 20010330
WO 2001-US29968 20010925
US 2000-186059P 20000229 (60)
US 2000-220042P 20000721 (60)
US 2000-187447P 20000307 (60)
US 2000-211673P 20000615 (60)
US 2000-235049P 20000925 (60)

US 2000-191863P 20000324 (60)
US 2000-193919P 20000331 (60)
US 2000-235032P 20000925 (60)
DT Utility
FS APPLICATION
LREP JOHN W. FREEMAN, ESQ., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 97 Drawing Page(s)
LN.CNT 51652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted. The invention still further provides isolated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 proteins, fusion proteins, antigenic peptides and anti-20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 40 OF 154 USPATFULL on STN
AN 2003:194506 USPATFULL
TI 14815, a human kinase family member and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003134317 A1 20030717
US 6759222 B2 20040706
AI US 2003-335711 A1 20030102 (10)
PRAI US 2002-345853P 20020102 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5192
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 14815 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14815 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14815 gene has been introduced or

disrupted. The invention still further provides isolated 14815 proteins, fusion proteins, antigenic peptides and anti-14815 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 41 OF 154 USPATFULL on STN
AN 2003:188692 USPATFULL
TI Novel human genes and methods of use thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2003130485 A1 20030710
AI US 2002-176306 A1 20020620 (10)
RLI Continuation-in-part of Ser. No. US 2001-1137, filed on 14 Nov 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US45291, filed on 14 Nov 2001, PENDING
PRAI WO 2001-US49416 20011218
WO 2001-US46717 20011022
US 2000-248362P 20001114 (60)
US 2000-248331P 20001114 (60)
US 2000-248365P 20001114 (60)
US 2000-250077P 20001130 (60)
US 2000-250327P 20001130 (60)
US 2000-250176P 20001130 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 60 Drawing Page(s)
LN.CNT 26835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted. The invention still further provides isolated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 proteins, fusion proteins, antigenic peptides and anti-47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 42 OF 154 USPATFULL on STN
AN 2003:187835 USPATFULL
TI Methods of using 5433, a human calcium channel family member

IN Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003129625 A1 20030710
AI US 2002-245121 A1 20020917 (10)
PRAI US 2001-322983P 20010917 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 5433 nucleic acid molecules, which encode calcium channel family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 5433 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 5433 gene has been introduced or disrupted. The invention still further provides isolated 5433 proteins, fusion proteins, antigenic peptides and anti-5433 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 43 OF 154 USPATFULL on STN
AN 2003:173317 USPATFULL
TI 32132, a novel fucosyltransferase family member and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
PI US 2003119161 A1 20030626
AI US 2001-844948 A1 20010427 (9)
PRAI US 2000-200604P 20000428 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5346
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32132 nucleic acid molecules, which encode novel fucosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32132 gene has been introduced or disrupted. The invention still further provides isolated 32132 proteins, fusion proteins, antigenic peptides and anti-32132 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 44 OF 154 USPATFULL on STN
AN 2003:172663 USPATFULL
TI Methods of using 46828, a human acyl-CoA synthetase
IN Hunter, John Joseph, Somerville, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003118507 A1 20030626
AI US 2002-245537 A1 20020917 (10)
PRAI US 2001-322920P 20010917 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated nucleic acids molecules, designated 46828 nucleic acid molecules, which encode AMP-binding enzymes, and in particular acyl-CoA synthases are disclosed. The invention provides methods of modulating the differentiation, proliferation, and/or inducing the cell killing of 46828-expressing hyperproliferative cells, e.g., 46828-expressing malignant cells from the lung, colon and ovaries. The invention further provides methods of treating, preventing and ***diagnosing*** solid tumors, soft tissue tumors, and/or metastatic lesions.

L16 ANSWER 45 OF 154 USPATFULL on STN
AN 2003:165985 USPATFULL
TI 8105, a novel human sugar transporter family member and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
Gu, Wei, Brookline, MA, UNITED STATES
PI US 2003113841 A1 20030619
AI US 2002-144624 A1 20020513 (10)
PRAI US 2001-290288P 20010511 (60)
DT Utility
FS APPLICATION
LREP LAURIE BUTLER LAWRENCE, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 8105 nucleic acid molecules, which encode novel sugar transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 8105 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 8105 gene has been introduced or disrupted. The invention still further provides isolated 8105 proteins, fusion proteins, antigenic peptides and anti-8105 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 46 OF 154 USPATFULL on STN
AN 2003:159431 USPATFULL
TI Methods of using 279, a human G protein-coupled protein receptor
IN Logan, Thomas Joseph, Needham, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003109044 A1 20030612
AI US 2002-267811 A1 20021009 (10)

PRAI US 2001-329648P 20011016 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 279 nucleic acid molecules, which encode human G protein-coupled receptor (GPCR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 279 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 279 gene has been introduced or disrupted. The invention still further provides isolated 279 proteins, fusion proteins, antigenic peptides and anti-279 antibodies. Methods utilizing compositions of the invention to treat, prevent or ***diagnose*** angiogenic disorders, e.g., cardiovascular and cancerous disorders, are also provided.

L16 ANSWER 47 OF 154 USPATFULL on STN
AN 2003:146274 USPATFULL
TI 50352, a human ubiquitin-protein ligase family member and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003100020 A1 20030529
AI US 2002-268036 A1 20021009 (10)
PRAI US 2001-327820P 20011009 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4865
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 50352 nucleic acid molecules, which encode novel ubiquitin-protein ligase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 50352 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 50352 gene has been introduced or disrupted. The invention still further provides isolated 50352 proteins, fusion proteins, antigenic peptides and anti-50352 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 48 OF 154 USPATFULL on STN
AN 2003:146256 USPATFULL
TI 46694, a human alpha/beta hydrolase family member and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003100001 A1 20030529
AI US 2002-289148 A1 20021106 (10)

PRAI US 2001-334225P 20011129 (60)
DT Utility
FS APPLICATION
LREP Paul J. Paglierani, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46694 nucleic acid molecules, which encode novel alpha/beta hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46694 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46694 gene has been introduced or disrupted. The invention still further provides isolated 46694 proteins, fusion proteins, antigenic peptides and anti-46694 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 49 OF 154 USPATFULL on STN
AN 2003:146246 USPATFULL
TI Methods of using 33751, a human potassium channel family member
IN Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003099991 A1 20030529
AI US 2002-255532 A1 20020926 (10)
PRAI US 2001-325854P 20010927 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 5473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated nucleic acids molecules, designated 33751 nucleic acid molecules, which encode a human potassium channel family member, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33751 gene has been introduced or disrupted. Isolated 33751 proteins, fusion proteins, antigenic peptides and anti-33751 antibodies are also disclosed. The invention provides, inter alia, methods of modulating 33751 activity or expression, thereby modulating pain or nociceptive responses in a subject. The invention further provides methods of treating, preventing and ***diagnosing*** neural disorders.

L16 ANSWER 50 OF 154 USPATFULL on STN
AN 2003:142947 USPATFULL
TI 32140, a novel human aldehyde dehydrogenase and uses therefor
IN Meyers, Rachel, Newton, MA, United States
Cook, William J., Natick, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.

corporation)
PI US 6569657 B1 20030527
AI US 2000-717926 20001121 (9)
PRAI US 2000-214707P 20000627 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Pak, Yong
LREP Alston & Bird LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 4612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32140 nucleic acid molecules, which encode novel aldehyde dehydrogenase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32140 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32140 gene has been introduced or disrupted. The invention still further provides isolated 32140 proteins, fusion proteins, antigenic peptides and anti-32140 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 51 OF 154 USPATFULL on STN
AN 2003:140551 USPATFULL
TI 21163, a novel human prolyl oligopeptidase and uses therefor
IN Hunter, John Joseph, Somerville, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003096392 A1 20030522
AI US 2001-25950 A1 20011219 (10)
PRAI US 2000-257736P 20001222 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 21163 nucleic acid molecules, which encode novel prolyl oligopeptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21163 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21163 gene has been introduced or disrupted. The invention still further provides isolated 21163 proteins, fusion proteins, antigenic peptides and anti-21163 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 52 OF 154 USPATFULL on STN
AN 2003:140464 USPATFULL
TI Novel human membrane-associated protein and cell surface protein family

members

IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES

PI US 2003096305 A1 20030522

AI US 2002-162435 A1 20020604 (10)

RLI Continuation-in-part of Ser. No. US 2001-836499, filed on 17 Apr 2001, PENDING

PRAI WO 2001-US12420 20010417
WO 2001-US19963 20010625
WO 2001-US16013 20010518
WO 2001-US20055 20010621
WO 2002-US275 20020108
WO 2001-US41811 20010821
US 2000-197507P 20000418 (60)
US 2000-214220P 20000623 (60)
US 2000-205674P 20000519 (60)
US 2000-213963P 20000623 (60)
US 2001-260286P 20010108 (60)
US 2000-226612P 20000821 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 22 Drawing Page(s)

LN.CNT 30445

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid molecules, which encode novel human membrane-associated protein family members, and human cell surface protein family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or disrupted. The invention still further provides isolated 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins, antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 53 OF 154 USPATFULL on STN

AN 2003:134569 USPATFULL

TI Novel human enzyme family members and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PI US 2003092658 A1 20030515

AI US 2002-175696 A1 20020620 (10)

RLI Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002, PENDING

PRAI US 2001-266140P 20010202 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 21384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 54 OF 154 USPATFULL on STN
AN 2003:133963 USPATFULL
TI 84604 and 84614, human anion transporter family members and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
Ferriera, Holly M., Norton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003092048 A1 20030515
AI US 2002-252646 A1 20020923 (10)
PRAI US 2001-325106P 20010926 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5870
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 84604 or 84614 nucleic acid molecules, which encode novel anion transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 84604 or 84614 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 84604 or 84614 gene has been introduced or disrupted. The invention still further provides isolated 84604 or 84614 proteins, fusion proteins, antigenic peptides and anti-84604 or 84614 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 55 OF 154 USPATFULL on STN
AN 2003:133421 USPATFULL
TI Methods of using 22417, a novel human aminoprotease family member
IN Hunter, John Joseph, Somerville, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003091506 A1 20030515
AI US 2002-245538 A1 20020917 (10)
PRAI US 2001-322924P 20010917 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4744
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 22417 nucleic acid molecules, which encode novel aminoprotease members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22417 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22417 gene has been introduced or disrupted. The invention still further provides isolated 22417 proteins, fusion proteins, antigenic peptides and anti-22417 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 56 OF 154 USPATFULL on STN
AN 2003:127169 USPATFULL
TI 25501, a human transferase family member and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003087382 A1 20030508
AI US 2002-217168 A1 20020812 (10)
PRAI US 2001-312539P 20010815 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25501 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25501 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25501 gene has been introduced or disrupted. The invention still further provides isolated 25501 proteins, fusion proteins, antigenic peptides and anti-25501 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 57 OF 154 USPATFULL on STN
AN 2003:127037 USPATFULL
TI 93870, a human G-protein coupled receptor and uses therefor
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003087249 A1 20030508
AI US 2002-85233 A1 20020228 (10)
PRAI US 2001-272677P 20010301 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 93870 nucleic acid molecules, which encode GPCRs. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 93870 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 93870 gene has been introduced or disrupted. The invention still further provides isolated 93870 proteins, fusion proteins, antigenic peptides and anti-93870 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 58 OF 154 USPATFULL on STN
AN 2003:120304 USPATFULL
TI 24554, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor
IN Libermann, Rosana K., Chestnut Hill, MA, UNITED STATES
Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003082785 A1 20030501
AI US 2002-269848 A1 20021011 (10)
PRAI US 2001-329218P 20011012 (60)
DT Utility
FS APPLICATION
LREP Paul J. Paglierani, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 24554 nucleic acid molecules, which encode novel ubiquitin carboxy-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 24554 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 24554 gene has been introduced or disrupted. The invention still further provides isolated 24554 proteins, fusion proteins,

antigenic peptides and anti-24554 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 59 OF 154 USPATFULL on STN
AN 2003:120237 USPATFULL
TI 52908, a human potassium channel, and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003082718 A1 20030501
AI US 2002-192440 A1 20020710 (10)
PRAI US 2001-341953P 20011219 (60)
US 2001-304243P 20010710 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5676
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acid molecules, designated 52908 nucleic acid molecules, which encode novel 52908-related potassium channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 52908 gene has been introduced or disrupted. The invention still further provides isolated 52908 proteins, fusion proteins, antigenic peptides and anti-52908 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 60 OF 154 USPATFULL on STN
AN 2003:113015 USPATFULL
TI 96829, a human transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003077748 A1 20030424
AI US 2002-264104 A1 20021003 (10)
PRAI US 2001-326906P 20011003 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 96829 nucleic acid molecules, which encode novel transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 96829 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 96829 gene has been introduced or disrupted. The invention still further provides isolated 96829 proteins,

fusion proteins, antigenic peptides and anti-96829 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 61 OF 154 USPATFULL on STN
AN 2003:106746 USPATFULL
TI 47619 and 47621, human ion channels, and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003073658 A1 20030417
AI US 2002-192116 A1 20020710 (10)
PRAI US 2001-304257P 20010710 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals , Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acid molecules, designated 47619 and 47621 nucleic acid molecules, which encode novel 47619 and 47621-related ion channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47619 and 47621 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 47619 and 47621 gene has been introduced or disrupted. The invention still further provides isolated 47619 and 47621 proteins, fusion proteins, antigenic peptides and anti-47619 and 47621 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 62 OF 154 USPATFULL on STN
AN 2003:106187 USPATFULL
TI 65577, a human matrix metalloproteinase and uses therefor
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003073098 A1 20030417
AI US 2002-103377 A1 20020321 (10)
PRAI US 2001-278347P 20010323 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 65577 nucleic acid molecules, which encode matrix metalloproteinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 65577 gene has been introduced

or disrupted. The invention still further provides isolated 65577 proteins, fusion proteins, antigenic peptides and anti-65577 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 63 OF 154 USPATFULL on STN
AN 2003:93080 USPATFULL
TI Novel nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003064439 A1 20030403
AI US 2002-164966 A1 20020607 (10)
RLI Continuation-in-part of Ser. No. US 2001-34864, filed on 27 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-996194, filed on 28 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-908928, filed on 19 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-908180, filed on 18 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-887389, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-789300, filed on 20 Feb 2001, GRANTED, Pat. No. US 6458576
PRAI US 2000-258517P 20001228 (60)
US 2000-250348P 20001130 (60)
US 2000-250073P 20001130 (60)
US 2000-253878P 20001129 (60)
US 2000-250338P 20001130 (60)
US 2000-220465P 20000720 (60)
US 2000-219740P 20000720 (60)
US 2000-214138P 20000626 (60)
US 2000-183208P 20000217 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 63 Drawing Page(s)
LN.CNT 27929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules that encode novel ***polypeptides*** . The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 64 OF 154 USPATFULL on STN
AN 2003:78529 USPATFULL
TI 63744, a human sugar transporter family member and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003054449 A1 20030320
AI US 2002-62960 A1 20020131 (10)
PRAI US 2001-265757P 20010201 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 63744 nucleic acid molecules, which encode novel sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 63744 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 63744 gene has been introduced or disrupted. The invention still further provides isolated 63744 proteins, fusion proteins, antigenic peptides and anti-63744 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 65 OF 154 USPATFULL on STN
AN 2003:71415 USPATFULL
TI 22108 and 47916, novel human thioredoxin family members and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PI US 2003049700 A1 20030313
AI US 2001-963339 A1 20010925 (9)
PRAI US 2000-235049P 20000925 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 22108 and 47916 nucleic acid molecules, which encode novel thioredoxin members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22108 or 47916 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22108 or 47916 gene has been introduced or disrupted. The invention still further provides isolated 22108 or 47916 proteins, fusion proteins, antigenic peptides and anti-22108 or 47916 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 66 OF 154 USPATFULL on STN
AN 2003:71379 USPATFULL
TI 87144, human amino acid transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003049664 A1 20030313
AI US 2002-191398 A1 20020709 (10)
PRAI US 2001-306108P 20010717 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4822
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 87144 nucleic acid molecules, which encode novel amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 87144 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 87144 gene has been introduced or disrupted. The invention still further provides isolated 87144 proteins, fusion proteins, antigenic peptides and anti-87144 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 67 OF 154 USPATFULL on STN
AN 2003:64812 USPATFULL
TI 96895, a human sodium-hydrogen exchanger family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
Ferriera, Holly M., Norton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003044933 A1 20030306
AI US 2002-217096 A1 20020812 (10)
PRAI US 2001-312554P 20010815 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 96895 nucleic acid molecules, which encode novel sodium-hydrogen exchanger family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 96895 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 96895 gene has been introduced or disrupted. The invention still further provides isolated 96895 proteins, fusion proteins, antigenic peptides and anti-96895 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 68 OF 154 USPATFULL on STN
AN 2003:57908 USPATFULL
TI 32229, a novel human acyl-CoA dehydrogenase family member and uses

thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Hunter, John J., Somerville, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2003040474 A1 20030227
AI US 2001-999314 A1 20011022 (9)
PRAI US 2000-242211P 20001020 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32229 nucleic acid molecules, which encode novel acyl-CoA dehydrogenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32229 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32229 gene has been introduced or disrupted. The invention still further provides isolated 32229 proteins, fusion proteins, antigenic peptides and anti-32229 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 69 OF 154 USPATFULL on STN
AN 2003:57427 USPATFULL
TI 46798, a human matrix metalloproteinase and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003039991 A1 20030227
AI US 2002-50216 A1 20020116 (10)
PRAI US 2001-262252P 20010116 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5002
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46798 nucleic acid molecules, which encode matrix metalloproteinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46798 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 46798 gene has been introduced or disrupted. The invention still further provides isolated 46798 proteins, fusion proteins, antigenic peptides and anti-46798 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the
invention are also provided.

L16 ANSWER 70 OF 154 USPATFULL on STN
AN 2003:44781 USPATFULL
TI 48120, 23479 and 46689, novel human hydrolases and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2003032091 A1 20030213
AI US 2001-971490 A1 20011005 (9)
PRAI US 2000-238170P 20001005 (60)
US 2000-237991P 20001005 (60)
DT Utility
FS APPLICATION
LREP LOUIS MEYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 7627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 23479, 48120, and 46689 nucleic acid molecules, which encode novel hydrolases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23479, 48120, and 46689 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23479, 48120, or 46689 gene has been introduced or disrupted. The invention still further provides isolated 23479, 48120, and 46689 proteins, fusion proteins, antigenic peptides and anti-23479, 48120, or 46689 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 71 OF 154 USPATFULL on STN
AN 2003:38357 USPATFULL
TI 68730 and 69112, protein kinase molecules and uses therefor
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003028004 A1 20030206
AI US 2001-24036 A1 20011217 (10)
PRAI US 2000-258222P 20001222 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acid molecules, designated 68730 and 69112 nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68730 and 69112 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68730 and 69112 gene has been introduced or disrupted. The invention still further provides isolated 68730 and 69112 proteins, fusion proteins, antigenic peptides and anti-68730 and anti-69112 antibodies. ***Diagnostic***

and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 72 OF 154 USPATFULL on STN
AN 2003:37671 USPATFULL
TI 16051a and 16051b, novel human PDZ family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PI US 2003027316 A1 20030206
AI US 2001-836499 A1 20010417 (9)
PRAI US 2000-197507P 20000418 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 16051a and 16051b nucleic acid molecules, which encode novel PDZ family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a or 16051b nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a or 16051b gene has been introduced or disrupted. The invention still further provides isolated 16051a or 16051b proteins, fusion proteins, antigenic peptides and anti-16051a or 16051b antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 73 OF 154 USPATFULL on STN
AN 2003:30272 USPATFULL
TI 85080, a human metal ion transporter family member and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003022219 A1 20030130
AI US 2002-186511 A1 20020701 (10)
PRAI US 2001-305260P 20010713 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4965
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 85080 nucleic acid molecules, which encode novel metal transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 85080 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 85080 gene has been introduced or disrupted. The invention still further provides isolated 85080 proteins, fusion proteins, antigenic peptides and anti-85080 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 74 OF 154 USPATFULL on STN
AN 2003:30265 USPATFULL
TI 65649, a human metalloprotease family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003022212 A1 20030130
AI US 2002-167555 A1 20020612 (10)
PRAI US 2001-297938P 20010613 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 65649 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65649 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 65649 gene has been introduced or disrupted. The invention still further provides isolated 65649 proteins, fusion proteins, antigenic peptides and anti-65649 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 75 OF 154 USPATFULL on STN
AN 2003:30258 USPATFULL
TI 98359, a sodium channel beta 4 subunit, and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003022205 A1 20030130
AI US 2002-142201 A1 20020509 (10)
PRAI US 2001-289893P 20010509 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides an isolated nucleic acid molecule encoding a novel human sodium channel protein .beta. subunit. This nucleic acid molecule encodes a transmembrane protein that bears substantially sequence similarity to mammalian sodium channel protein .beta. subunits. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated ***polypeptides*** , fusion ***polypeptides*** ,

antigenic peptides and antibodies. ***Diagnostic*** , screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and ***polypeptides*** of the present invention are useful as modulating agents in regulating a variety of cellular processes.

L16 ANSWER 76 OF 154 USPATFULL on STN
AN 2003:30254 USPATFULL
TI 68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003022201 A1 20030130
AI US 2002-107695 A1 20020327 (10)
PRAI US 2001-279184P 20010327 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 68999 nucleic acid molecules, which encode ubiquitin carboxyl-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68999 gene has been introduced or disrupted. The invention still further provides isolated 68999 proteins, fusion proteins, antigenic peptides and anti-68999 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 77 OF 154 USPATFULL on STN
AN 2003:30248 USPATFULL
TI 59914 and 59921, choline transporters and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003022195 A1 20030130
AI US 2002-62937 A1 20020131 (10)
PRAI US 2001-267076P 20010201 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5980
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 59914 and 59921 nucleic acid molecules, which encode choline transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 59914 and 59921 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which 59914 and

59921 genes have been introduced or disrupted. The invention still further provides isolated 59914 and 59921 proteins, fusion proteins, antigenic peptides and anti-59914 and 59921 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 78 OF 154 USPATFULL on STN
AN 2003:23732 USPATFULL
TI 56294 and 56629, novel human metalloproteases and uses thereof
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PI US 2003017572 A1 20030123
AI US 2001-961656 A1 20010924 (9)
PRAI US 2000-235035P 20000925 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 56294 and 56229 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56294 or 56629nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56294 or 56629 gene has been introduced or disrupted. The invention still further provides isolated 56294 or 56629 proteins, fusion proteins, antigenic peptides and anti-56294, anti-56629 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 79 OF 154 USPATFULL on STN
AN 2003:23729 USPATFULL
TI 2150, human protein kinase family member and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003017569 A1 20030123
AI US 2002-184563 A1 20020627 (10)
PRAI US 2001-301702P 20010628 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4485
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 2150 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2150 nucleic acid molecules,

host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2150 gene has been introduced or disrupted. The invention still further provides isolated 2150 proteins, fusion proteins, antigenic peptides and anti-2150 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 80 OF 154 USPATFULL on STN
AN 2003:11319 USPATFULL
TI 46584, a human transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003009024 A1 20030109
AI US 2002-170528 A1 20020613 (10)
PRAI US 2001-298012P 20010613 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46584 nucleic acid molecules, which encode transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46584 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46584 gene has been introduced or disrupted. The invention still further provides isolated 46584 proteins, fusion proteins, antigenic peptides and anti-46584 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 81 OF 154 USPATFULL on STN
AN 2003:11312 USPATFULL
TI 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
IN Leiby, Kevin R., Natick, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Glucksmann, Maria A., Lexington, MA, UNITED STATES
PI US 2003009017 A1 20030109
AI US 2001-12140 A1 20011108 (10)
PRAI US 2000-246768P 20001108 (60)
US 2000-246772P 20001108 (60)
US 2000-249185P 20001115 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 6763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 38650, 28472, 5495, 65507, 81588 or 14354 nucleic acid molecules, which encode novel adenosine deaminase, glycoprotease, or seven transmembrane receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38650, 28472, 5495, 65507, 81588 or 14354 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38650, 28472, 5495, 65507, 81588 or 14354 gene has been introduced or disrupted. The invention still further provides isolated 38650, 28472, 5495, 65507, 81588 or 14354 proteins, fusion proteins, antigenic peptides and anti-38650, 28472, 5495, 65507, 81588 or 14354 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 82 OF 154 USPATFULL on STN

AN 2003:3504 USPATFULL

TI 67108, a human phospholipid transporter family member and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003003539 A1 20030102

AI US 2002-170102 A1 20020612 (10)

PRAI US 2001-297840P 20010613 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 5762

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 67108 nucleic acid molecules, which encode novel phospholipid transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 67108 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 67108 gene has been introduced or disrupted. The invention still further provides isolated 67108 proteins, fusion proteins, antigenic peptides and anti-67108 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 83 OF 154 USPATFULL on STN

AN 2002:343977 USPATFULL

TI 65552, a human matrix metalloproteinase and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002197703 A1 20021226

AI US 2002-163316 A1 20020605 (10)

PRAI US 2001-297863P 20010613 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)
LN.CNT 4981
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 65552 nucleic acid molecules, which encode matrix metalloproteinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65552 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 65552 gene has been introduced or disrupted. The invention still further provides isolated 65552 proteins, fusion proteins, antigenic peptides and anti-65552 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 84 OF 154 USPATFULL on STN
AN 2002:343969 USPATFULL
TI 80090, 52874, 52880, 63497, and 33425 methods and compositions of human proteins and uses thereof
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002197695 A1 20021226
AI US 2001-80960 A1 20011019 (10)
PRAI US 2000-242040P 20001020 (60)
US 2000-242038P 20001020 (60)
US 2000-241992P 20001020 (60)
US 2000-242637P 20001023 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 6340
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, which encode novel fucosyltransferase, seven transmembrane receptor, or RhoGAP family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80090, 52874, 52880, 63497, or 33425 gene has been introduced or disrupted. The invention still further provides isolated 80090, 52874, 52880, 63497, or 33425 proteins, fusion proteins, antigenic peptides and anti-80090, 52874, 52880, 63497, or 33425 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 85 OF 154 USPATFULL on STN
AN 2002:338212 USPATFULL
TI 69624, a novel human transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002193582 A1 20021219
AI US 2002-173519 A1 20020617 (10)

PRAI US 2001-298970P 20010618 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 69624 nucleic acid molecules, which encode novel transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69624 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69624 gene has been introduced or disrupted. The invention still further provides isolated 69624 proteins, fusion proteins, antigenic peptides and anti-69624 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 86 OF 154 USPATFULL on STN
AN 2002:337938 USPATFULL
TI 58860, a human cholesteryl ester hydrolase and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc.
PI US 2002193303 A1 20021219
AI US 2002-56744 A1 20020125 (10)
PRAI US 2001-264167P 20010125 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 58860 nucleic acid molecules, which encode cholesteryl ester hydrolases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58860 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 58860 gene has been introduced or disrupted. The invention still further provides isolated 58860 proteins, fusion proteins, antigenic peptides and anti-58860 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 87 OF 154 USPATFULL on STN
AN 2002:336850 USPATFULL
TI 15985, a novel human serine/threonine protein kinase family member and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002192204 A1 20021219
AI US 2001-934406 A1 20010821 (9)

PRAI US 2000-226740P 20000821 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 15985 nucleic acid molecules, which encode novel serine/threonine protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15985 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15985 gene has been introduced or disrupted. The invention still further provides isolated 15985 proteins, fusion proteins, antigenic peptides and anti-15985 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 88 OF 154 USPATFULL on STN
AN 2002:329459 USPATFULL
TI 15368, a novel human GTP-releasing factor family member and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002187138 A1 20021212
AI US 2001-922199 A1 20010802 (9)
PRAI US 2000-222622P 20000802 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 4492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 15368 nucleic acid molecules, which encode novel GTP-releasing factor family member family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15368 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15368 gene has been introduced or disrupted. The invention still further provides isolated 15368 proteins, fusion proteins, antigenic peptides and anti-15368 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 89 OF 154 USPATFULL on STN
AN 2002:322472 USPATFULL
TI 53010, a novel human carboxylesterase family member and uses thereof
IN Curtis, Rory A. J., Southborough, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PI US 2002182636 A1 20021205
US 6664091 B2 20031216
AI US 2001-23515 A1 20011218 (10)

PRAI US 2000-256369P 20001218 (60)
US 2001-279508P 20010328 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4777
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 53010 nucleic acid molecules, which encode novel carboxylesterase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53010 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53010 gene has been introduced or disrupted. The invention still further provides isolated 53010 proteins, fusion proteins, antigenic peptides and anti-53010 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 90 OF 154 USPATFULL on STN
AN 2002:301198 USPATFULL
TI 59079 and 12599, protein kinase family members and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Acton, Susan L., Lexington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002168742 A1 20021114
AI US 2002-77130 A1 20020215 (10)
PRAI US 2001-269201P 20010215 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 59079 and 12599 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 59079 or 12599 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 59079 or 12599 gene has been introduced or disrupted. The invention still further provides isolated 59079 and 12599 proteins, fusion proteins, antigenic peptides and anti-59079 and anti-12599 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 91 OF 154 USPATFULL on STN
AN 2002:301169 USPATFULL
TI 46980, a novel human neuroligin family member and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002168713 A1 20021114
AI US 2001-875353 A1 20010606 (9)
PRAI US 2000-209949P 20000606 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46980 nucleic acid molecules, which encode novel neuroligin members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46980 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46980 gene has been introduced or disrupted. The invention still further provides isolated 46980 proteins, fusion proteins, antigenic peptides and anti-46980 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 92 OF 154 USPATFULL on STN
AN 2002:301125 USPATFULL
TI 14691, a human glutamate receptor family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002168668 A1 20021114
AI US 2002-106534 A1 20020326 (10)
PRAI US 2001-279086P 20010327 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 14691 nucleic acid molecules, which encode novel glutamate receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14691 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14691 gene has been introduced or disrupted. The invention still further provides isolated 14691 proteins, fusion proteins, antigenic peptides and anti-14691 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 93 OF 154 USPATFULL on STN
AN 2002:295307 USPATFULL
TI 38554, 57301 and 58324, human organic ion transporters and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002165357 A1 20021107
AI US 2002-95139 A1 20020311 (10)
PRAI US 2001-275172P 20010312 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 7172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 38554, 57301 or 58324 nucleic acid molecules, which encode novel SLC21 or SLC22 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38554, 57301 or 58324 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38554, 57301 or 58324 gene has been introduced or disrupted. The invention still further provides isolated 38554, 57301 or 58324 proteins, fusion proteins, antigenic peptides and anti-38554, 57301 or 58324 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 94 OF 154 USPATFULL on STN
AN 2002:294726 USPATFULL
TI 32144, a novel human fatty acid amide hydrolase family member and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2002164769 A1 20021107
AI US 2001-966614 A1 20010927 (9)
PRAI US 2000-238054P 20001005 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5256
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32144 nucleic acid molecules, which encode novel fatty acid amide hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32144 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32144 gene has been introduced or disrupted. The invention still further provides isolated 32144 proteins, fusion proteins, antigenic peptides and anti-32144 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 95 OF 154 USPATFULL on STN
AN 2002:294723 USPATFULL
TI 57406, a novel human metalloprotease family member and uses thereof
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PI US 2002164766 A1 20021107
AI US 2001-7271 A1 20011022 (10)
PRAI US 2000-242303P 20001020 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 57406 nucleic acid molecules, which encode novel metalloprotease members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57406 nucleic acid molecules, host cells into that the expression vectors have been introduced, and nonhuman transgenic animals in that a 57406 gene has been introduced or disrupted. The invention still further provides isolated 57406 proteins, fusion proteins, antigenic peptides and anti-57406 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 96 OF 154 USPATFULL on STN
AN 2002:294703 USPATFULL
TI 47174, a novel human glycosyltransferase and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002164746 A1 20021107
US 6703230 B2 20040309
AI US 2001-973457 A1 20011009 (9)
PRAI US 2000-238849P 20001006 (60)
DT Utility
FS APPLICATION
LREP LOUIS MEYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** neurological disorders are disclosed.

L16 ANSWER 97 OF 154 USPATFULL on STN
AN 2002:294702 USPATFULL

TI 53320, a novel human acyltransferase and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PI US 2002164745 A1 20021107
AI US 2001-882872 A1 20010615 (9)
PRAI US 2000-212077P 20000615 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 53320 nucleic acid molecules, which encode novel acyltransferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53320 gene has been introduced or disrupted. The invention still further provides isolated 53320 proteins, fusion proteins, antigenic peptides and anti-53320 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The 53320 nucleic acids are expressed in endothelial cells.

L16 ANSWER 98 OF 154 USPATFULL on STN
AN 2002:294282 USPATFULL
TI 56939, a novel human acyl-CoA thioesterase family member and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002164320 A1 20021107
AI US 2001-911317 A1 20010723 (9)
PRAI US 2000-220040P 20000721 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5096
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 56939 nucleic acid molecules, which encode novel acyl-CoA thioesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56939 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56939 gene has been introduced or disrupted. The invention still further provides isolated 56939 proteins, fusion proteins, antigenic peptides and anti-56939 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 99 OF 154 USPATFULL on STN
AN 2002:287589 USPATFULL

TI 25206, a novel human short-chain dehydrogenase/reductase family member and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
PI US 2002160452 A1 20021031
AI US 2001-997816 A1 20011129 (9)
PRAI US 2000-250186P 20001130 (60)
DT Utility
FS APPLICATION
LREP P. LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4862
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25206 nucleic acid molecules, which encode novel short-chain dehydrogenase/reductase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25206 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25206 gene has been introduced or disrupted. The invention still further provides isolated 25206 proteins, fusion proteins, antigenic peptides and anti-25206 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 100 OF 154 USPATFULL on STN
AN 2002:287508 USPATFULL
TI 56739, a novel CUB domain containing protein and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002160371 A1 20021031
AI US 2001-886429 A1 20010621 (9)
PRAI US 2000-213963P 20000623 (60)
DT Utility
FS APPLICATION
LREP LOUIS MAYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 56739 nucleic acid molecules, which encode novel CUB family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56739 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56739 gene has been introduced or disrupted. The invention still further provides isolated 56739 proteins, fusion proteins, antigenic peptides and anti-56739 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 101 OF 154 USPATFULL on STN
AN 2002:280557 USPATFULL
TI 32620, a novel human sodium-sugar symporter family member and uses

thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002156002 A1 20021024
AI US 2001-928530 A1 20010813 (9)
PRAI US 2000-227068P 20000822 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32620 nucleic acid molecules, which encode novel sodium-sugar symporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32620 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32620 gene has been introduced or disrupted. The invention still further provides isolated 32620 proteins, fusion proteins, antigenic peptides and anti-32620 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 102 OF 154 USPATFULL on STN
AN 2002:273565 USPATFULL
TI 84242,8035, 55304, 52999, and 21999, novel human proteins and methods of use thereof
IN Bandaru, Rajaschkar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002151696 A1 20021017
AI US 2001-996194 A1 20011128 (9)
PRAI US 2000-250348P 20001130 (60)
US 2000-250073P 20001130 (60)
US 2000-253878P 20001129 (60)
US 2000-250338P 20001130 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 8034
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 8035, 84242, 55304, 52999, or 21999 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 8035, 84242, 55304, 52999, or 21999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 8035, 84242, 55304, 52999, or 21999 gene has been introduced or disrupted. The invention still further provides isolated 8035, 84242, 55304, 52999, or 21999 proteins, fusion proteins, antigenic peptides and anti-8035, anti-84242, anti-55304, anti-52999, or anti-21999 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 103 OF 154 USPATFULL on STN
AN 2002:272795 USPATFULL
TI 43716, a novel human G-protein and uses thereof
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002150916 A1 20021017
AI US 2001-972529 A1 20011005 (9)
PRAI US 2000-237716P 20001005 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47316 nucleic acid molecules, which encode novel G-protein family members, preferably Ras family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47316 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47316 gene has been introduced or disrupted. The invention still further provides isolated 47316 proteins, fusion proteins, antigenic peptides and anti-47316 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 104 OF 154 USPATFULL on STN
AN 2002:272789 USPATFULL
TI 33410, a novel human carboxylesterase family member and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002150910 A1 20021017
AI US 2001-934323 A1 20010821 (9)
PRAI US 2000-226774P 20000821 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33410 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33410 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33410 gene has been introduced or disrupted. The invention still further provides isolated 33410 proteins, fusion proteins, antigenic peptides and anti-33410 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 105 OF 154 USPATFULL on STN
AN 2002:265924 USPATFULL
TI 48921, a novel human GTP releasing factor and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002146800 A1 20021010
AI US 2001-940836 A1 20010827 (9)
PRAI US 2000-228760P 20000830 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 48921 nucleic acid molecules, which encode novel GTP releasing factor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 48921 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 48921 gene has been introduced or disrupted. The invention still further provides isolated 48921 proteins, fusion proteins, antigenic peptides and anti-48921 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 106 OF 154 USPATFULL on STN
AN 2002:251234 USPATFULL
TI 14087, a novel serine protease molecule and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002137181 A1 20020926
AI US 2001-910151 A1 20010718 (9)
PRAI US 2000-219022P 20000718 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 14087 nucleic acid molecules, which encode novel serine protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14087 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14087 gene has been introduced or disrupted. The invention still further provides isolated 14087 proteins, fusion proteins, antigenic peptides and anti-14087 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 107 OF 154 USPATFULL on STN
AN 2002:251157 USPATFULL
TI 46638, a novel human lipoxygenase family member and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002137101 A1 20020926
AI US 2001-862658 A1 20010521 (9)
PRAI US 2000-205675P 20000519 (60)
DT Utility
FS APPLICATION
LREP DIANA M. COLLAZO, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46638 nucleic acid molecules, which encode novel lipoxygenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46638 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46638 gene has been introduced or disrupted. The invention still further provides isolated 46638 proteins, fusion proteins, antigenic peptides and anti-46638 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 108 OF 154 USPATFULL on STN
AN 2002:251119 USPATFULL
TI 57242, a novel human G protein-coupled receptor family member and uses therefor
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Gimeno, Ruth, Wellesley, MA, UNITED STATES
White, David, Braintree, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002137063 A1 20020926
AI US 2001-942374 A1 20010829 (9)
PRAI US 2000-228409P 20000829 (60)
DT Utility
FS APPLICATION
LREP Kerri Pollard Schray, Millennium Pharmaceuticals, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 104
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4723
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for the ***diagnosis*** and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, hyperlipidemia, overweight anorexia, or cachexia. The invention provides isolated nucleic acids molecules, designated 57242 nucleic acid molecules, which encode novel G protein-coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57242 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57242 gene has been introduced or disrupted. The invention still further provides isolated 57242 proteins, fusion proteins, antigenic peptides and anti-57242 antibodies. Methods of use of the provided 57242 compositions for screening, ***diagnostic*** and

therapeutic methods in connection with metabolic disorders are also disclosed.

L16 ANSWER 109 OF 154 USPATFULL on STN
AN 2002:243117 USPATFULL
TI 69318, a human sodium/calcium exchanger (transporter) family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002132303 A1 20020919
AI US 2002-94214 A1 20020308 (10)
PRAI US 2001-275078P 20010312 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 69318 nucleic acid molecules, which encode novel sodium/calcium exchanger family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69318 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69318 gene has been introduced or disrupted. The invention still further provides isolated 69318 proteins, fusion proteins, antigenic peptides and anti-69318 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 110 OF 154 USPATFULL on STN
AN 2002:243115 USPATFULL
TI 25466, a human transporter family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002132301 A1 20020919
AI US 2002-74547 A1 20020212 (10)
PRAI US 2001-269072P 20010215 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4778
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25466 nucleic acid molecules, which encode novel transporter molecules. The 25466 transporter molecules are homologous to monocarboxylate (MCT) transporters, and in particular to SLC16 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25466 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25466 gene has been introduced or disrupted. The invention still further provides isolated 25466 proteins, fusion proteins, antigenic peptides and anti-25466 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the
invention are also provided.

L16 ANSWER 111 OF 154 USPATFULL on STN
AN 2002:235461 USPATFULL
TI 32468, a human sugar transporter family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002127650 A1 20020912
AI US 2002-94059 A1 20020308 (10)
PRAI US 2001-275053P 20010312 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32468 nucleic acid molecules, which encode novel sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32468 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32468 gene has been introduced or disrupted. The invention still further provides isolated 32468 proteins, fusion proteins, antigenic peptides and anti-32468 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 112 OF 154 USPATFULL on STN
AN 2002:235379 USPATFULL
TI 47324, a novel human G-protein and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002127568 A1 20020912
AI US 2001-945173 A1 20010831 (9)
PRAI US 2000-229293P 20000901 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47324 nucleic acid molecules, which encode novel G-protein family members, preferably Ras family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47324 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47324 gene has been introduced or disrupted. The invention still further provides isolated 47324 proteins, fusion proteins, antigenic peptides and anti-47324 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 113 OF 154 USPATFULL on STN
AN 2002:235378 USPATFULL
TI 52991, a novel human transporter and uses therefor
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
PI US 2002127567 A1 20020912
AI US 2001-942447 A1 20010829 (9)
PRAI US 2000-229036P 20000831 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4581
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 52991 nucleic acid molecules, which encode novel transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52991 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52991 gene has been introduced or disrupted. The invention still further provides isolated 52991 proteins, fusion proteins, antigenic peptides and anti-52991 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 114 OF 154 USPATFULL on STN
AN 2002:228315 USPATFULL
TI 32626, a novel human UDP-glycosyltransferase and uses thereof
IN Leiby, Kevin R., Natick, MA, UNITED STATES
Spaltmann, Frank, Cambridge, MA, UNITED STATES
Cook, William James, Natick, MA, UNITED STATES
PI US 2002123475 A1 20020905
AI US 2001-895728 A1 20010629 (9)
PRAI US 2000-215749P 20000630 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32626 nucleic acid molecules, which encode novel UDP-glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32626 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32626 gene has been introduced or disrupted. The invention still further provides isolated 32626 proteins, fusion proteins, antigenic peptides and anti-32626 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 115 OF 154 USPATFULL on STN
AN 2002:221771 USPATFULL
TI 61833, a novel human pyridoxyl-dependent decarboxylase family member and uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PI US 2002119913 A1 20020829
AI US 2001-841880 A1 20010424 (9)
PRAI US 2000-199559P 20000425 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 61833 nucleic acid molecules, which encode novel pyridoxyl-dependent decarboxylase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 61833 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 61833 gene has been introduced or disrupted. The invention still further provides isolated 61833 proteins, fusion proteins, antigenic peptides and anti-61833 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 116 OF 154 USPATFULL on STN
AN 2002:221414 USPATFULL
TI 53014, a human metalloprotease family member and uses therefor
IN Bandaru, Rajasehkar, Watertown, MA, UNITED STATES
Curtis, Rory A.J., Southborough, MA, UNITED STATES
Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PI US 2002119555 A1 20020829
AI US 2001-14070 A1 20011113 (10)
PRAI US 2000-258373P 20001222 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 6025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 53014 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53014 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53014 gene has been introduced or disrupted. The invention still further provides isolated 53014 proteins, fusion proteins, antigenic peptides and anti-53014 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 117 OF 154 USPATFULL on STN
AN 2002:221383 USPATFULL
TI 67073, a human phospholipid transporter family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002119523 A1 20020829
AI US 2002-41395 A1 20020108 (10)
PRAI US 2001-262216P 20010117 (60)
US 2001-289358P 20010508 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 67073 nucleic acid molecules, which encode novel phospholipid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 67073 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 67073 gene has been introduced or disrupted. The invention still further provides isolated 67073 proteins, fusion proteins, antigenic peptides and anti-67073 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 118 OF 154 USPATFULL on STN
AN 2002:213801 USPATFULL
TI 16816 and 16839, novel human phospholipase C molecules and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Rudolph-Owen, Laura S., Jamaica Plains, MA, UNITED STATES
Tsai, Fong Ying, Newton, MA, UNITED STATES
PI US 2002115178 A1 20020822
AI US 2001-908664 A1 20010717 (9)
PRAI US 2000-218675P 20000717 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4734
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 16816 or 16839 nucleic acid molecules, which encode novel phospholipase C family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16816 or 16839 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16816 or 16839 gene has been introduced or disrupted. The invention still further provides isolated 16816 or 16839 proteins, fusion proteins, antigenic peptides and anti-16816 or 16839 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 119 OF 154 USPATFULL on STN
AN 2002:213761 USPATFULL
TI 22406, a novel human pyridoxal-phosphate dependent enzyme family member and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002115137 A1 20020822
US 6458576 B2 20021001
AI US 2001-789300 A1 20010220 (9)
PRAI US 2000-183208P 20000217 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 22406 nucleic acid molecules, which encode a novel pyridoxal-phosphate dependent enzyme family member. In particular, the invention relates to 22406 serine racemase ***polypeptide*** and encoding nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22406 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22406 gene has been introduced or disrupted. The invention still further provides isolated 22406 proteins, fusion proteins, antigenic peptides and anti-22406 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 120 OF 154 USPATFULL on STN
AN 2002:206613 USPATFULL
TI 25219, a novel human aminotransferase and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002111310 A1 20020815
AI US 2001-972528 A1 20011005 (9)
PRAI US 2000-238131P 20001006 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated aminotransferase nucleic acids molecules, designated 25219 nucleic acid molecules, which encode novel 25219 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25219 nucleic acid molecules, host cells into which the expression vectors have been

introduced, and nonhuman transgenic animals in which a 25219 gene has been introduced or disrupted. The invention still further provides isolated 25219 proteins, fusion proteins, antigenic peptides and anti-25219 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 121 OF 154 USPATFULL on STN
AN 2002:206610 USPATFULL
TI 46508, a novel human peptidyl-tRNA hydrolase family member and uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2002111307 A1 20020815
AI US 2001-888911 A1 20010625 (9)
PRAI US 2000-213688P 20000623 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46508 nucleic acid molecules, which encode novel peptidyl-tRNA hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46508 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46508 gene has been introduced or disrupted. The invention still further provides isolated 46508 proteins, fusion proteins, antigenic peptides and anti-46508 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 122 OF 154 USPATFULL on STN
AN 2002:199265 USPATFULL
TI 26199, 33530, 33949, 47148, 50226, and 58764, novel human transferase family members and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
MacBeth, Kyle, Boston, MA, UNITED STATES
PI US 2002107376 A1 20020808
AI US 2001-924358 A1 20010806 (9)
PRAI US 2000-229300P 20000901 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 6380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, or 58764 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression

vectors containing 26199, 33530, 33949, 47148, 50226, or 58764 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, or 58764 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, or 58764 proteins, fusion proteins, antigenic peptides and anti-26199, -33530, -33949, -47148, -50226, or -58764 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 123 OF 154 USPATFULL on STN
AN 2002:198674 USPATFULL
TI 32544, a novel human phospholipase C and uses thereof
IN Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002106774 A1 20020808
AI US 2001-927112 A1 20010810 (9)
PRAI US 2000-246808P 20001108 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 124 OF 154 USPATFULL on STN
AN 2002:198670 USPATFULL
TI 25233, a novel human aminotransferase and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002106770 A1 20020808
AI US 2001-908928 A1 20010719 (9)
PRAI US 2000-220465P 20000720 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 4268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25233 nucleic acid molecules, which encode novel aminotransferase family

members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25233 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25233 gene has been introduced or disrupted. The invention still further provides isolated 25233 proteins, fusion proteins, antigenic peptides and anti-25233 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 125 OF 154 USPATFULL on STN
AN 2002:174981 USPATFULL
TI 18232, a novel dual specificity phosphatase and uses therefor
IN Meyers, Rachel A., Newton, MA, United States
Weich, Nadine, Brookline, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6420153 B1 20020716
AI US 2000-704139 20001101 (9)
PRAI US 2000-185772P 20000229 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Pak, Yong
LREP Fish & Richardson P.C.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 4450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

L16 ANSWER 126 OF 154 USPATFULL on STN
AN 2002:172478 USPATFULL
TI 54370, a novel human sulfate transporter and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002091238 A1 20020711
AI US 2001-938970 A1 20010824 (9)
PRAI US 2000-228762P 20000830 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23

ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 54370 nucleic acid molecules, which encode novel transporter family members, preferably sulfate transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 54370 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 54370 gene has been introduced or disrupted. The invention still further provides isolated 54370 proteins, fusion proteins, antigenic peptides and anti-54370 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 127 OF 154 USPATFULL on STN
AN 2002:171961 USPATFULL
TI 57800, a novel human cadherin and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002090710 A1 20020711
AI US 2001-972086 A1 20011004 (9)
PRAI US 2000-237698P 20001005 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 4465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 57800 nucleic acid molecules, which encode novel cadherin family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57800 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57800 gene has been introduced or disrupted. The invention still further provides isolated 57800 proteins, fusion proteins, antigenic peptides and anti-57800 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 128 OF 154 USPATFULL on STN
AN 2002:171950 USPATFULL
TI 27439, novel human hydroxylase and uses therefor
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PI US 2002090699 A1 20020711
AI US 2001-945301 A1 20010831 (9)
PRAI US 2000-229301P 20000901 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)

LN.CNT 4656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 27439 nucleic acid molecules, which encode novel hydroxylases, preferably Cytochrome P450 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27439 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27439 gene has been introduced or disrupted. The invention still further provides isolated 27439 proteins, fusion proteins, antigenic peptides and anti-27439 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 129 OF 154 USPATFULL on STN
AN 2002:171878 USPATFULL
TI 27419, a novel human arginine-N-methyl transferase and uses thereof
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002090627 A1 20020711
AI US 2001-970638 A1 20011003 (9)
PRAI US 2000-237717P 20001005 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 27419 nucleic acid molecules, which encode novel methyltransferase family members, preferably arginine methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27419 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27419 gene has been introduced or disrupted. The invention still further provides isolated 27419 proteins, fusion proteins, antigenic peptides and anti-27419 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 130 OF 154 USPATFULL on STN
AN 2002:164787 USPATFULL
TI 56638, a novel human neprilysin protease and uses thereof
IN Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PI US 2002086405 A1 20020704
AI US 2001-928531 A1 20010813 (9)
PRAI US 2000-235035P 20000925 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 56638 nucleic acid molecules, which encode novel neprilysin family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56638 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56638 gene has been introduced or disrupted. The invention still further provides isolated 56638 proteins, fusion proteins, antigenic peptides and anti-56638 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** pain or pain related disorders are disclosed.

L16 ANSWER 131 OF 154 USPATFULL on STN

AN 2002:157608 USPATFULL

TI 7716, a novel human ATPase and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002082212 A1 20020627

AI US 2001-908180 A1 20010718 (9)

PRAI US 2000-219740P 20000720 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 4113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 7716 nucleic acid molecules, which encode novel ATPase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7716 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7716 gene has been introduced or disrupted. The invention still further provides isolated 7716 proteins, fusion proteins, antigenic peptides and anti-7716 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 132 OF 154 USPATFULL on STN

AN 2002:157606 USPATFULL

TI 56201, a novel human sodium ion channel family member and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002082210 A1 20020627

AI US 2001-875363 A1 20010605 (9)

PRAI US 2000-209238P 20000605 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 5052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 56201 nucleic acid molecules, which encode novel ion channel members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56201 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56201 gene has been introduced or disrupted. The invention still further provides isolated 56201 proteins, fusion proteins, antigenic peptides and anti-56201 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 133 OF 154 USPATFULL on STN
AN 2002:157080 USPATFULL
TI NARC8 programmed cell-death-associated molecules and uses thereof
IN Chiang, Lillian Wei-Ming, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002081679 A1 20020627
AI US 2001-775009 A1 20010201 (9)
RLI Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000, PENDING
PRAI US 1999-161188P 19991022 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated NARC8 nucleic acid molecules, which encode novel programmed cell death-associated proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing NARC8 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a NARC8 gene has been introduced or disrupted. The invention still further provides isolated NARC8 proteins, fusion proteins, antigenic peptides and anti-NARC8 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 134 OF 154 USPATFULL on STN
AN 2002:157058 USPATFULL
TI 21784, a novel human calcium channel family member and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002081657 A1 20020627
AI US 2001-875423 A1 20010605 (9)
PRAI US 2000-209257P 20000605 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)

LN.CNT 5663
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 21784 nucleic acid molecules, which encode novel calcium channel members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21784 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21784 gene has been introduced or disrupted. The invention still further provides isolated 21784 proteins, fusion proteins, antigenic peptides and anti-21784 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 135 OF 154 USPATFULL on STN
AN 2002:149154 USPATFULL
TI 32225, a novel human alpha/beta hydrolase family member and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002077310 A1 20020620
AI US 2001-896578 A1 20010629 (9)
PRAI US 2000-214948P 20000629 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32225 nucleic acid molecules, which encode novel .alpha./.beta. hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32225 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32225 gene has been introduced or disrupted. The invention still further provides isolated 32225 proteins, fusion proteins, antigenic peptides and anti-32225 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 136 OF 154 USPATFULL on STN
AN 2002:148635 USPATFULL
TI 33428, a novel human metalloprotease family member and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Cook, William James, Natick, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002076778 A1 20020620
AI US 2001-858068 A1 20010515 (9)
PRAI US 2000-204159P 20000515 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5308

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33428 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33428 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33428 gene has been introduced or disrupted. The invention still further provides isolated 33428 proteins, fusion proteins, antigenic peptides and anti-33428 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 137 OF 154 USPATFULL on STN
AN 2002:148611 USPATFULL
TI 31939, a novel human leucine-rich repeat family member and uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PI US 2002076753 A1 20020620
AI US 2001-822687 A1 20010330 (9)
PRAI US 2000-193919P 20000331 (60)
DT Utility
FS APPLICATION
LREP LOUIS M. MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5039
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 31939 nucleic acid molecules, which encode novel leucine-rich repeat (LRR) members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 31939 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 31939 gene has been introduced or disrupted. The invention still further provides isolated 31939 proteins, fusion proteins, antigenic peptides and anti-31939 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 138 OF 154 USPATFULL on STN
AN 2002:148610 USPATFULL
TI 33395, a novel human leucine-rich repeat family member and uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PI US 2002076752 A1 20020620
AI US 2001-815626 A1 20010323 (9)
PRAI US 2000-191863P 20000324 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33395 nucleic acid molecules, which encode novel leucine rich repeat

(LRR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33395 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33395 gene has been introduced or disrupted. The invention still further provides isolated 33395 proteins, fusion proteins, antigenic peptides and anti-33395 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 139 OF 154 USPATFULL on STN
AN 2002:141504 USPATFULL
TI 33428, a novel human metalloprotease family member and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Cook, William James, Natick, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002072490 A1 20020613
AI US 2001-858081 A1 20010515 (9)
PRAI US 2000-204159P 20000515 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33428 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33428 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33428 gene has been introduced or disrupted. The invention still further provides isolated 33428 proteins, fusion proteins, antigenic peptides and anti-33428 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 140 OF 154 USPATFULL on STN
AN 2002:133840 USPATFULL
TI 13237, 18480, 2245 or 16228 novel human protein kinase molecules and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plains, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Tsai, Fong Ying, Newton, MA, UNITED STATES
PI US 2002068698 A1 20020606
AI US 2001-910150 A1 20010718 (9)
PRAI US 2000-219028P 20000718 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 5427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245 or 16228 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245 or 16228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245 or 16228 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245 or 16228 proteins, fusion proteins, antigenic peptides and anti-13237, -18480, -2245 or -16228 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 141 OF 154 USPATFULL on STN
AN 2002:133440 USPATFULL
TI 32252, a novel human AMP-binding family member and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Hunter, John J., Somerville, MA, UNITED STATES
PI US 2002068291 A1 20020606
AI US 2001-882836 A1 20010615 (9)
PRAI US 2000-211730P 20000615 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 5439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32252 nucleic acid molecules, which encode novel AMP-binding enzyme members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32252 gene has been introduced or disrupted. The invention still further provides isolated 32252 proteins, fusion proteins, antigenic peptides and anti-32252 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 142 OF 154 USPATFULL on STN
AN 2002:120026 USPATFULL
TI 54372, a novel human anion transporter and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002062015 A1 20020523
AI US 2001-942446 A1 20010829 (9)
PRAI US 2000-229121P 20000831 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 4614
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 54372 nucleic acid molecules, which encode novel transporter family members, preferably anion transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 54372 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 54372 gene has been introduced or disrupted. The invention still further provides isolated 54372 proteins, fusion proteins, antigenic peptides and anti-54372 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 143 OF 154 USPATFULL on STN
AN 2002:119592 USPATFULL
TI 27803, a novel human adenylate kinase family member and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002061575 A1 20020523
AI US 2001-925108 A1 20010808 (9)
PRAI US 2000-224035P 20000809 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 27803 nucleic acid molecules, which encode novel adenylate kinase family member family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27803 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27803 gene has been introduced or disrupted. The invention still further provides isolated 27803 proteins, fusion proteins, antigenic peptides and anti-27803 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 144 OF 154 USPATFULL on STN
AN 2002:119591 USPATFULL
TI 16658, 14223, and 16002, novel human kinases and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002061574 A1 20020523
AI US 2001-922138 A1 20010803 (9)
PRAI US 2000-229299P 20000901 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 4922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 16658, 14223, and 16002 nucleic acid molecules, which encode novel

kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16658, 14223, and 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16658, 14223, and 16002 gene has been introduced or disrupted. The invention still further provides isolated 16658, 14223, and 16002 proteins, fusion proteins, antigenic peptides and anti-16658, -14223, and -16002 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 145 OF 154 USPATFULL on STN
AN 2002:119590 USPATFULL
TI 18431 and 32374, novel human protein kinase family members and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002061573 A1 20020523
AI US 2001-916790 A1 20010727 (9)
PRAI US 2000-221543P 20000728 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 4936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 146 OF 154 USPATFULL on STN
AN 2002:105955 USPATFULL
TI 57658, a novel human uridine kinase and uses thereof
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
PI US 2002055161 A1 20020509
AI US 2001-896522 A1 20010628 (9)
PRAI US 2000-216503P 20000630 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 57658 nucleic acid molecules, which encode novel uridine kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57658 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57658 gene has been introduced or disrupted. The invention still further provides isolated 57658 proteins, fusion proteins, antigenic peptides and anti-57658 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 147 OF 154 USPATFULL on STN
AN 2002:105954 USPATFULL
TI 23680,a novel human aminotransferase and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002055159 A1 20020509
AI US 2001-883060 A1 20010615 (9)
PRAI US 2000-212079P 20000615 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5098
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 23680 nucleic acid molecules, which encode a novel human aminotransferase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23680 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 23680 gene has been introduced or disrupted. The invention still further provides isolated 23680 proteins, fusion proteins, antigenic peptides and anti-23680 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 148 OF 154 USPATFULL on STN
AN 2002:72636 USPATFULL
TI 47885, a novel human ubiquitin-activating enzyme and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002039773 A1 20020404
AI US 2001-905211 A1 20010712 (9)
PRAI US 2000-218041P 20000713 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 4166
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47885 nucleic acid molecules, which encode novel ubiquitin-activating enzyme family members. The invention also provides antisense nucleic

acid molecules, recombinant expression vectors containing 47885 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47885 gene has been introduced or disrupted. The invention still further provides isolated 47885 proteins, fusion proteins, antigenic peptides and anti-47885 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 149 OF 154 USPATFULL on STN
AN 2002:54654 USPATFULL
TI 46619, a novel human beta-ketoacyl synthase and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002031815 A1 20020314
AI US 2001-892870 A1 20010626 (9)
PRAI US 2000-214174P 20000626 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated and novel nucleic acids molecules, designated beta-ketoacyl synthase nucleic acid molecules, which encode novel beta-ketoacyl synthase ***polypeptides*** . The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing beta-ketoacyl synthase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a beta-ketoacyl synthase gene has been introduced or disrupted. The invention still further provides isolated beta-ketoacyl synthase proteins, fusion proteins, antigenic peptides and anti-beta-ketoacyl synthase antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 150 OF 154 USPATFULL on STN
AN 2002:43191 USPATFULL
TI 32447, a novel human acyltransferase and uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PI US 2002025557 A1 20020228
AI US 2001-887389 A1 20010622 (9)
PRAI US 2000-214138P 20000626 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32447 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules,

recombinant expression vectors containing 32447 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32447 gene has been introduced or disrupted. The invention still further provides isolated 32447 proteins, fusion proteins, antigenic peptides and anti-32447 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 151 OF 154 USPATFULL on STN
AN 2002:27601 USPATFULL
TI 46743 and 27417, novel human acyltransferase family members and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Macbeth, Kyle J., Boston, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PI US 2002016449 A1 20020207
AI US 2001-817910 A1 20010326 (9)
PRAI US 2000-192092P 20000324 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 5587
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 46743 or 27417 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46743 or 27417 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46743 or 27417 gene has been introduced or disrupted. The invention still further provides isolated 46743 or 27417 proteins, fusion proteins, antigenic peptides and anti-46743 or anti-27417 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 152 OF 154 USPATFULL on STN
AN 2002:16897 USPATFULL
TI 25552, a novel human methyltransferase family member and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
PI US 2002009777 A1 20020124
AI US 2001-816714 A1 20010323 (9)
PRAI US 2000-191865P 20000324 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 5107

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25552 nucleic acid molecules, which encode novel ubiE methyltransferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25552 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25552 gene has been introduced or disrupted. The invention still further provides isolated 25552 proteins, fusion proteins, antigenic peptides and anti-25552 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 153 OF 154 USPATFULL on STN
AN 2002:8237 USPATFULL
TI 27960, a novel ubiquitin conjugating enzyme family member and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PI US 2002004236 A1 20020110
AI US 2001-842528 A1 20010425 (9)
PRAI US 2000-199500P 20000425 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 27960 nucleic acid molecules, which encode novel ubiquitin-conjugating enzyme family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27960 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27960 gene has been introduced or disrupted. The invention still further provides isolated 27960 proteins, fusion proteins, antigenic peptides and anti-27960 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 154 OF 154 USPATFULL on STN
AN 2002:3832 USPATFULL
TI 21509 and 33770, novel human dehydrogenase family members and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2002001807 A1 20020103
AI US 2001-823901 A1 20010330 (9)
PRAI US 2000-193920P 20000331 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)

LN.CNT 5930
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 21509 or 33770 nucleic acid molecules, which encode novel dehydrogenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21509 or 33770 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21509 or 33770 gene has been introduced or disrupted. The invention still further provides isolated 21509 or 33770 proteins, fusion proteins, antigenic peptides and anti-21509 or 33770 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

=> logoff y
STN INTERNATIONAL LOGOFF AT 13:50:59 ON 27 APR 2005

Connection closed by remote host